(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 January 2006 (12.01.2006)

PCT

(10) International Publication Number
WO 2006/002854 A2

(51) International Patent Classification:
A61K 38/00 (2006.01)

(21) International Application Number:
PCT/EP2005/006906

(22) International Filing Date: 27 June 2005 (27.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/582,858 25 June 2004 (25.06.2004) US

(71) Applicant *(for all designated States except US)*: **LICENTIA, LTD.** [FI/FI]; Erottajankatu 19 B, 6th Floor, FIN-00130 Helsinki (FI).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALITALO, Kari** [FI/FI]; Molecular/Cancer Biology Laboratory, Biomedicum Helsinki, P.O. Box 63 (Haartmaninkatu 8), University of Helsinki, FIN-00014 Helsinki (FI). **LAAKKONEN, Pirjo** [FI/FI]; Molecular/Cancer Biology Laboratory,, Biomedicum Helsinki, P.O. Box 63 (Haartmaninkatu 8), University of Helsinki, Fin-00014 Helsinki (FI). **KUBO, Hajime** [JP/FI]; Molecular/Cancer Biology Laboratory, Biomedicum Helsinki, P.O. Box 63 (Haartmaninkatu 8), University of Helsinki, FIN-00014 Helsinki (FI). **SAINIO, Kirsi** [FI/FI]; Molecular/Cancer Biology Laboratory, Biomedicum Helsinki, P.O.B. 63 (Haartmaninkatu 8), University of Helsinki, FIN-00014 Helsinki (FI).

(74) Agents: **FINDEISEN, Marco** et al.; Witte, Weller & Partner, Postfach 105462, 70047 Stuttgart (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** TIE RECEPTOR AND TIE LIGAND MATERIALS AND METHODS FOR MODULATING FEMALE FERTILITY

(57) **Abstract:** The present invention provides materials and methods involving Tie receptors and Angiopoietin ligands for modulating female fertility in mammals, including humans. Materials and methods for inhibiting fertility (e.g., for contraception) or for enhancing fertility (e.g., treating infertility) are contemplated.

WO 2006/002854 A2

TIE RECEPTOR AND TIE LIGAND MATERIALS AND METHODS FOR MODULATING FEMALE FERTILITY

CROSS REFERENCE TO RELATED APPLICATIONS

The present application claims the priority benefit of United States Provisional Application No. 60/582,858, filed June 25, 2004, incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention provides materials and methods for modulating (inhibiting or enhancing) female fertility in mammals, including humans.

BACKGROUND OF THE INVENTION

Angiogenesis is the process in which new blood vessels are formed by capillary sprouting from the established vascular network in response to angiogenic stimuli. Following the proliferation and migration of endothelial cells, vessels need to be stabilized and matured into fully functional vessels in a process that requires recruitment and interaction of endothelial cells with mural cells and reconstitution of the surrounding extracellular matrix (ECM). In an adult, angiogenesis normally takes place only in wound healing, tissues repair, and during the female reproductive cycle and pregnancy. In addition, angiogenesis occurs in pathological conditions such as tumor progression, diabetic blindness, age-related macular degeneration, rheumatoid arthritis, psoriasis, and more than 70 other conditions. The balance between the positive and negative regulatory molecules is thought to regulate angiogenesis. The second vascular system of the body, the lymph vascular system, forms during development coincidentally with the maturation of the blood vessels from embryonic veins, through a process called lymphangiogenesis (reviewed in Saharinen et al., 2004).

Positive regulators of angiogenesis are fairly well characterized. Members of the vascular endothelial growth factor (VEGF) family and their receptors function during formation of the initial embryonic vascular plexus, whereas angiopoietins (Angs) and their receptor Tie-2 are implicated in the subsequent remodeling processes (reviewed in (Ferrara et al., Nat. Med., 9:669-676, 2003;

Rossant and Howard, Annu. Rev. Cell Dev. Biol., 18:541-573, 2002). Tie-1, an endothelial specific receptor tyrosine kinase, shares high degree of homology with Tie-2. These receptors contain two immunoglobulin-like loops, three EGF-like domains, and three fibronectin type III repeats in their extracellular domains, and tyrosine kinase domains with a number of phosphorylation and protein interactions sites in their cytoplasmic tails. The expression of the *tie* gene is restricted to the endothelial cells and to some hematopoietic cell lineages (Korhonen et al., Oncogene, 9:395-403, 1994; Partanen et al., Mol. Cell. Biol., 12:1698-1707, 1992). Upregulation of Tie-1 expression has been observed during wound healing, ovarian follicle maturation and tumor angiogenesis (Kaipainen et al., Cancer Res., 54:6571-6577, 1994; Korhonen et al., Blood, 80:2548-2555,1992). Abnormal expression of Ang-2, Tie-1 and Tie-2 was also detected in menorrhagic endometrium (Blumenthal et al., Fertil. Steril., 78:1294-1300, 2002).

Tie-1 is required during the embryonic development for the integrity and survival of vascular endothelial cells, particularly in the regions undergoing angiogenic growth of capillaries. Targeted disruption of the Tie-1 gene in mice results in embryonic lethality between E13.5 and E18.5, depending on the background strain, because of severe edema, extensive hemorrhage and defective microvessel integrity (Puri et al., EMBO J., 14:5884-5891, 1995; Sato et al., Nature, 376:70-74, 1995). The genetic deletion of Tie-2 results in embryonic lethality at E10.5 due to the cardiac failure, hemorrhage, and defects in vascular remodeling and maturation, resulting from improper recruitment of periendothelial supporting cells (Dumont et al., Genes Dev., 8:1897-1909, 1994; Sato et al., Nature, 376:70-74, 1995). Mice lacking both Tie-1 and Tie-2 receptors also die at about E10.5 with similar defects than Tie-2 null animals (Puri et al., Development, 126:4569-4580, 1999).

Tie-1 is an orphan receptor with no reported ligands, whereas three members of the angiopoietin family (Ang-1, Ang-2 and Ang-3/4) have been identified as ligands for Tie-2. Ang-1 and Ang-2 have been extensively studied over the last years. Ang-1 promotes vascular remodeling, maturation, and stabilization of the vasculature, and the Ang-1 null phenotype is very similar but slightly less severe than Tie-2 null phenotype resulting in embryonic lethality at E12.5 (Suri et al., Cell, 87:1171-1180, 1996). Overexpression of Ang-1 under the keratin-14 (K14) promoter

in the skin confirms the role of Ang-1 in endothelial proliferation and survival (Thurston et al., Science, 286:2511-2514,1999). Ang-2 is a natural antagonist for Tie-2 in endothelial cells and it is not absolutely required during embryonic development but is necessary during postnatal vascular remodeling. In addition, deletion of Ang-2 results in defects in the patterning and function of the lymphatic vasculature (Gale et al., Dev. Cell., 3:411-423, 2002). The lymphatic defect can be completely rescued by Ang-1, but not the defects in vascular remodeling suggesting that Ang-2 acts as a Tie-2 agonist in the lymphatic vasculature but as an antagonist in the blood vascular system (Gale et al., Dev. Cell., 3:411-423, 2002). Overexpression of Ang-2 in the blood vessels mimics the phenotype of Tie-2 null animals and leads to embryonic lethality at E9.5-E10.5 (Maisonpierre et al., Science, 277:55-60,1997). Ang-1 binding to Tie-2 induces phosphorylation of the receptor while binding of Ang-2 to Tie-2 is unable to induce phosphorylation of the receptor in endothelial cells (Maisonpierre et al., Science, 277:55-60, 1997). None of the angiopoietins have been reported to directly bind Tie-1.

SUMMARY OF THE INVENTION

The present invention includes compositions and methods of use thereof for the modulation of female fertility and embryogenesis.

In one aspect, the invention is a soluble Tie-1 receptor extracellular domain composition which is useful to inhibit female fertility and embryogenesis. Tie-1-Ig constructs expressed in mice were observed to stabilize ovarian vasculature, inhibiting its regression.

In humans, Tie-1 comprises a receptor tyrosine kinase protein of about 1138 amino acids (Swiss Prot database accession no. P35590 and U.S. Patent No. 5,955,291, both incorporated herein by reference). This Tie amino acid sequence comprises a signal peptide (aa 1-24) cleaved to yield a mature protein comprised of amino acids 25-1138. The extracellular domain comprises approximately amino acids 25-759, in which residues 43-105 comprises an Ig-like C2-type 1 domain; residues 83, 161, 503, 596, and 709 are putative N-linked glcyosylation sites; residues 214-256, 258-303, and 305-345 comprise EGF-like sequences; residues 372-426 comprise an Ig-like C2-type 2 domain; and residues 446-537, 545-637 and 644-736 comprise Fibronectin type-III-like domains. Residues 760-784 comprise the putative

transmembrane domain. For the practice of the present invention, fragments of the Tie 1 extracellular domain that are effective for inhibiting fertility or embryogenesis also may be used. Effective fragments may be identified by in vivo screening as described herein. Without being limited to a particular theory, fragments that contain sequences effective to interact with Tie-2 and/or angiopoietin ligands (that bind Tie-1, or Tie-2, or Tie-1/Tie-2 complexes) are specifically contemplated.

In one embodiment, the Tie-1 extracellular domain is fused to an immunoglobulin constant domain (Fc), and preferably to an IgG Fc domain. Fusion to such polypeptides to increase serum half-life (i.e., to slow clearance), is specifically contemplated. Further modifications, including pegylation or addition of other moieties to increase serum half-life also is contemplated.

Variants of the exact human Tie-1 sequence described herein also are contemplated. For example, polypeptides having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater percent identity to the Tie-1 receptor extracellular domain sequence described herein, or effective fragments thereof, are specifically contemplated.

The composition preferably further includes a pharmaceutically acceptable diluent, excipient, or carrier.

In a related embodiment, the invention is a soluble Tie-2 receptor extracellular domain composition which is useful to inhibit female fertility and embryogenesis. Human Tie-2 (Swiss Prot database accession no. Q02763, incorporated herein by reference), which has a similar structural organization as Tie-1, comprises an amino acid sequence of 1124 amino acids, of which about residues 1-22 comprise a signal peptide and residues 746-770 comprise the putative transmembrane domain.

For the practice of the present invention, fragments of the Tie-2 extracellular domain that are effective for inhibiting fertility or embryogenesis also may be used. Effective fragments may be identified by *in vivo* screening (as described herein with respect to Tie-1/Ig peptides). Without being limited to a particular theory, fragments that contain sequences effective to interact with Tie-1

and/or angiopoietin ligands (that bind Tie-2 or Tie-1/Tie-2 complexes) are specifically contemplated.

In one embodiment, the Tie-2 extracellular domain is fused to an immunoglobulin constant domain (Fc), and preferably to an IgG Fc domain. Fusion to such polypeptides to increase serum half-life (i.e., to slow clearance), is specifically contemplated. Further modifications, including pegylation or addition of other moieties to increase serum half life also is contemplated.

Variants of the exact human Tie-2 sequence described herein also are contemplated. For example, polypeptides having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater percent identity to the Tie-2 receptor extracellular domain sequence described herein, or effective fragments thereof, are specifically contemplated.

In another embodiment, the invention is the use of Tie-1 or Tie-2 compositions as described here for the manufacture of a medicament to modulate female fertility, e.g., as a contraceptive.

For these and other embodiments where polypeptides are contemplated as therapeutic agent, the invention also includes polynucleotides and vectors (e.g., gene therapy vectors such as adenoviruses, adeno-associated viruses, or lentiviruses) that encode the polypeptides and that can be used to express the polypeptides *ex vivo* or *in vivo*. Compositions comprising such polynucleotides or vectors and pharmaeceutically acceptable diluents or carriers are contemplated as additional aspects of the invention.

The invention also is a method of inhibiting fertility of a female mammal by administering to the mammal an amount of the polypeptide or polynucleotide materials described herein effective to inhibit fertility. All routes of administration (oral, intravenous intramuscular or other injection, skin patch, topical, vaginal, etc.) are contemplated.

Without intending to be limited to a particular theory, the soluble Tie materials are effective for inhibiting fertility by binding circulating angiopoietin molecules and preventing them from stimulating Tie-1/Tie-2 expressed in the female

reproductive system. In another variation, the invention is the use of angiopoietin antibodies or short interfering RNA or antisense molecules or other angiopoietin inhibitors to inhibit female fertility.

The invention also includes compositions comprising an angiopoetin-1 polypeptide for use in manufacture of a medicament to promote fertility and embryogenesis in a subject. The invention further includes compositions comprising an angiopoeitin-2 molecule for use in manufacturing a medicament to promote fertility and embryogenesis in a female subject. In an additional embodiment, the compositions contemplated by the invention further comprise a pharmaceutically acceptable diluent or carrier. The invention includes methods of administering such compositions to a female subject to increase fertility or reduce the likelihood of miscarriages. Administration after ovulation (which can be estimated from body temperature or other monitoring of the female cycle) is specifically contemplated.

As described above with reference to the Tie peptides, the use of fragments and sequence variants for the angiopoietins to treat infertility is specifically contemplated.

Administration of polynucleotides (or vectors) that encode the angiopoietin polypeptides also is contemplated, and use of such polypeptides and polypeptides for manufacture of a medicament to treat infertility is contemplated.

In another aspect, the invention provides a method for modulating female fertility comprising the step of administering to a subject a Tie-1 extracellular domain composition in an amount effective to modulate fertility in the subject. In one aspect, the Tie-1 composition inhibits fertility and inhibits embryogenesis in the subject.

The invention also provides a method for promoting fertility in an subject comprising the step of administering to a subject an Angiopoetin-1 composition in an amount effective to promote fertility in a subject. Promoting fertility includes promoting implantation of an embryo, or promoting growth of an embryo.

Yet another aspect of the invention is a method of screening for infertility in a female, or screening for a biochemical pathway that may be contributing to infertility in a female, comprising measuring Tie receptor expression or activity in a biological sample (e.g., a tissue or fluid sample or biopsy) from a mammalian female, wherein Tie expression or activity correlates with fertility. Teilman and Christensen recently reported in Cell Biol. International (2005) that the Tie-1 and Tie-2 receptors localize to the primary cilia in the female reproductive organs, such as ovarian surface epithelium in humans. Without intending to be limited to a particular theory, aberrant Tie receptor expression or function in these tissues is suggested as causative or correlative with human infertility. In a preferred variation, screening methods are performed using a biological sample that comprises female reproductive tissue, such as ovary, fallopian tube, uterine tissue, or the like. In a highly preferred variation, the biological sample comprises primary cilia of ovarian surface endothelium. In a related variation, the invention comprises analyzing Tie receptor sequence for a mutation that disrupts Tie-1/Tie-2 interactions or Tie/angiopietin interactions.

Yet another variation of the invention is methods of screening for agents that modify female fertility by modulating the interactions between Tie-1 and/or Tie-2 and/or angiopoeitins. More specifically, agents that disrupt the normal interactions between circulating agonist angiopoietin Tie ligands and Tie receptors expressed in the female reproductive system are expected to inhibit fertility and have utility as a contraceptive agent, and agents that mimic or enhance such interactions have utility for promoting fertility.

The following numbered paragraphs summarize additional aspects and embodiments of the invention:

1. A method of modulating fertility or embryogenesis in a mammalian female, comprising:

administering to a mammalian female a medicament comprising a modulator of angiopoietin-induced Tie receptor activity in cells of the female, in an amount effective to modulate fertility or embryogenesis in the female. For the purposes of the invention, "fertility" refers to the ability to conceive and bear viable

offspring. The invention is applicable to any mammals but is of particular interest to humans, pets (e.g., dogs, cats), animals of importance to agricultural or sporting (horses, cows, pigs, oxen), endanagered species, and zoo animals. The terms "modulate" refers to both up-regulation (increase fertility) and down-regulation or inhibition (decrease or eliminate fertility).

2. Use of a modulator of angiopoietin-induced Tie receptor activity in the manufacture of a medicament to modulate fertility or embryogenesis in a mammalian female.

3. The method or use of paragraphs 1 or 2, wherein the female is human.

4. The method or use of any one of paragraphs 1-3, wherein the medicament further comprises a pharmaceutically acceptable diluent, excipient or carrier. Appropriate carriers will be apparent for various agents and chosen routes of administration.

5. The method or use of any one of paragraphs 1-4, wherein the modulator is an inhibitor of angiopoietin-induced Tie receptor activity, and the modulator is present in the medicament in an amount effective to inhibit fertility or embryogenesis. Tie receptor activity can be measured in vitro by screening for phosphorylation of the receptor or downstream physiological processes of cells that express the receptor.

6. The method or use of paragraph 5, wherein the inhibitor comprises a soluble polypeptide that binds to an angiopoietin protein and comprises an amino acid sequence that is at least 80% identical to the extracellular domain amino acid sequence of a mammalian Tie-1 or Tie-2 receptor tyrosine kinase.

7. The method or use of paragraph 5, wherein the inhibitor comprises a member selected from the group consisting of:

(A) a polypeptide that comprises:

(i) an amino acid sequence that is at least 80% identical to amino acids 25-759 of SEQ ID NO: 2;

(ii) an amino acid sequence that is at least 80% identical to amino acids 24-745 of SEQ ID NO: 4; and

(iii) fragments of (i) or (ii);

wherein the polypeptide binds at least one angiopoietin polypeptide selected from the group consisting of Angiopoietin-1 (SEQ ID NO: 6), Angiopoietin-2 (SEQ ID NO: 8), Angiopoietin-3 (SEQ ID NO: 10), and Angiopoietin-4 (SEQ ID NO: 12);

(B) polynucleotides that comprise a nucleotide sequence that encode a polypeptide according to (A); and

(C) vectors that comprise a polynucleotide according to (B).

8. A method or use according to paragraph 6 or 7, wherein the polypeptide further comprises an immunoglobulin Fc fragment.

9. The method or use according to paragraph 8, wherein the immunoglobulin Fc fragment comprises an IgG Fc domain.

10. The method or use according to paragraph 5, wherein the inhibitor comprises an antibody substance that specifically immunoreacts to the extracellular domain of a Tie-1 or Tie-2 receptor tyrosine kinase, wherein the antibody substance comprises: (a) a monoclonal or polyclonal antibody; (b) a fragment of (a) that retains said immunoreactivity; or (c) a polypeptide that comprises an antigen binding fragment of (a) and that retains said immunoreactivity.

11. The method according to paragraph 5, wherein the inhibitor comprises an interfering RNA that inhibits expression of a polypeptide selected from the group consisting of a Tie-1 receptor tyrosine kinase, a Tie-2 receptor tyrosine kinase; Angiopoietin-1, Angiopoietin-2, Angiopoietin-3, and Angiopoietin-4.

12. The method or use according to any one of paragraphs 1-4, wherein the modulator is an agonist of Tie receptor activity, and is present in the medicament in an amount effective to increase fertility or promote embryogenesis in the female.

13. The method or use of paragraph 12, wherein the agonist comprises (a) a polypeptide that comprises an amino acid sequence at least 80% identical to a mammalian angiopoietin polypeptide or fragments thereof that is effective to bind and stimulate a Tie receptor tyrosine kinase; or (b) a polynucleotide that comprises a nucleotide sequence that encodes said polypeptide; or (c) a vector that comprises the polynucleotide.

14. The method or use according to paragraph 13, wherein the angiopoietin polypeptide is selected from group consisting of human angiopoietin-1 (SEQ ID NO: 6), angiopoietin-2 (SEQ ID NO: 8), angiopoietin-3 (SEQ ID NO: 10), and angiopoietin-4 (SEQ ID NO: 12).

15. The method or use according to any one of paragraphs 1-14, wherein the medicament is administered orally, by intravenous injection, by intramuscular injection, or other injection, by transdermal patch, topically or vaginally.

16. The method according to any one of paragraphs 1-14, wherein the medicament is administered after ovulation.

17. A method of screening for infertility in a female, comprising measuring Tie receptor expression or activity in a biological sample from a mammalian female, wherein Tie expression or activity correlates with fertility.

18. The method of paragraph 17, wherein the biological sample comprises primary cilia of ovarian surface endothelium.

19. A method of screening for modulators of binding between a Tie receptor tyrosine kinase and an angiopoietin ligand, comprising:

a) contacting a Tie receptor composition with an angiopoietin ligand in the presence and in the absence of a putative modulator compound;

b) measuring binding between the Tie receptor and the angiopoietin ligand in the presence and absence of the putative modulator compound; and

c) identifying a modulator compound based on a decrease or increase in said binding in the presence of the putative modulator compound, as compared to binding in the absence of the putative modulator compound.

20. A method according to paragraph 19, wherein the Tie receptor composition comprises a cell that expresses Tie-1 receptor on its surface.

21. A method according to paragraph 20, wherein the cell further expresses Tie-2 receptor on its surface.

22. A method according to any one of paragraphs 19-21, further comprising a step of:

(d) making a modulator composition by formulating a modulator identified according to step (c) in a pharmaceutically acceptable carrier.

23. A method according to paragraph 22, further comprising a step of:

(e) administering the modulator composition to a mammal that comprises cells that express Tie receptors, and determining physiological effects of the modulator composition in the mammal.

24. A method according to paragraph 23, comprising assessing fertility in mammal.

25. A method according to any one of paragraphs 19-24, wherein the Tie receptor is selected from the group consisting of a mammalian Tie-1 and a mammalian Tie-2 and mixtures thereof.

26. A method according to paragraph 25, wherein the Tie receptor and the angiopoietin are human.

Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, including the detailed description, and all such features are intended as aspects of the invention. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration

only, because various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

Moreover, features of the invention described herein can be re-combined into additional embodiments that also are intended as aspects of the invention, irrespective of whether the combination of features is specifically mentioned above as an aspect or embodiment of the invention. Also, only those limitations that are described herein as critical to the invention should be viewed as such; variations of the invention lacking features that have not been described herein as critical are intended as aspects of the invention.

With respect to aspects of the invention that have been described as a set or genus, every individual member of the set or genus is intended, individually, as an aspect of the invention, even if, for brevity, every individual member has not been specifically mentioned herein. When aspects of the invention that are described herein as being selected from a genus, it should be understood that the selection can include mixtures of two or more members of the genus.

In addition to the foregoing, the invention includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations specifically described herein. Although the applicant(s) invented the full scope of the claims appended hereto, the claims appended hereto are not intended to encompass within their scope the prior art work of others. Therefore, in the event that statutory prior art within the scope of a claim is brought to the attention of the applicants by a Patent Office or other entity or individual, the applicant(s) reserve the right to exercise amendment rights under applicable patent laws to redefine the subject matter of such a claim to specifically exclude such statutory prior art or obvious variations of statutory prior art from the scope of such a claim. Variations of the invention defined by such amended claims also are intended as aspects of the invention.

DETAILED DESCRIPTION

The present invention involves the fields of cell and molecular biology, and many standard techniques relevant to those fields will be relevant to the practice

of the present invention. Many such techniques are described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989), and/or Ausubel et al., eds., Current Protocols in Molecular Biology, Green Publishers Inc. and Wiley and Sons, NY (1994-2001), both of which are incorporated by reference in their entirety.

A. Gene sequences of interest to the present invention.

At least two Tie receptors have been identified, referred to as Tie (Tie-1) and Tie-2. The DNA and deduced amino acid sequences of all known Angiopoietins and Tie receptors of any vertebrate species that have been reported in the literature are hereby incorporated by reference. However, due to their special signficance to the invention, the following table is provided for the convenience of the reader:

Molecule	Genbank Accession Number	SEQ ID NO:
Human Tie-1	NP_005415	SEQ ID NO: 1 and 2
Human Tie-2	Q02763; NP_000450	SEQ ID NO: 3 and 4
Hu Angiopoietin-1	NM001146	SEQ ID NO: 5 and 6
Hu Angiopoietin-2	NM001147	SEQ ID NO: 7 and 8
Hu Angiopoietin-3	AF074332	SEQ ID NO: 9 and 10
Hu Angiopoietin-4	AF113708	SEQ ID NO: 11 and 12

The Angiopoietin Family Members

The Angiopoietins are of special interest to the present invention because they have been found to modulate (stimulate or inhibit) Tie-2. The angiopoietin (Ang 1-4) family of molecules were originally identified by cDNA library screening for ligands to the orphan Tie 2 receptor tyrosine kinase. [Davis et al., Cell, 87: 1161 69 (1996)]. Ang 1, the first of the angiopoietin ligands identified, was isolated through secretion trap expression cloning using cell lines which demonstrated binding of secreted factors to Tie 2 Fc molecules. This novel technique isolated a 498 amino acid, 70 kDa glycoprotein. The N terminal region of the protein showed hydrophobic sequences characteristic of secretory signal sequences. Residues 100-280 of Ang 1 resemble a coiled coil structure like that found in myosin, while residues 280-498 show homology to a family of proteins which includes fibrinogen,

thus this region is the fibrinogen-like domain. Ang-1 shows a binding affinity to Tie 2 less than 4 nM, and induces phosphorylation and activation of the Tie 2 tyrosine kinase.

The remaining members of the angiopoietin family were isolated using homology searches against the Ang-1 cDNA sequence. Human Ang-2 , a 496 amino acid protein (Maisonpierre et al, Science. 277: 55 60 (1997)), shows 85% homology to mouse Ang-2 and 60% homology to the Human Ang-1 protein. Ang-2 possesses an amino-terminal secretory signal sequence also found in Ang-1, and also both the coiled coil and fibrinogen-like domains. Ang-2 also shares 8 of the 9 cysteine residues found throughout the Ang-1 sequence, believed to be important in disulfide bond formation. Analysis of Ang-2 activity on the Tie 2 receptor shows that Ang-2 binds to Tie 2 but does not induce phosphorylation of the receptor, implicating Ang-2 as an antagonist to Ang-1 activation of Tie 2.

Angiopoietin 3 has been isolated by several groups based on sequence similarity to Ang-1 and Ang-2. See, e.g., Kim et al., FEBS Lett. 443: 353 6 (1999); Nishimura et al, FEBS Lett. 448: 254 6 (1999). The groups identified either a 503 or 491 amino acid clone of Ang-3, respectively. Nishimura et al. cloned Ang-3 from a human aorta cDNA library, and identified a 503 amino acid protein having 45.1% identity with human Ang-1 and 44.7% identity to Ang-2. A third group independently identified a 460 amino acid Ang-3 clone, (ANGPTL3) from human liver tissue. Conklin et al., Genomics, 62: 477 82 (1999). All three clones possess the characteristic N terminal secretory signal sequence, coiled coil motif, and fibrinogen like domains of the other angiopoietin family members.

Human Ang-4, identified by Valenzuela, et al (Proc. Natl. Acad. Sci USA. 96:1904 09. 1999), using sequence homology to a mouse genomic library, is a 503 amino acid protein having the leader signal sequence, coiled coil, and fibrinogen like sequences indicative of an angiopoietin family member. Both Ang-3 and Ang-4 show conservation of 8 of the 9 cysteines present in Ang-1. Both Ang-3 and Ang-4 have been reported to show binding to the Tie-2 receptor and not Tie-1. Ang-3 acts as an antagonist, while Ang-4 activates Tie-2 as an agonist.

In addition to the foregoing, the invention involves several other polypeptide factors involved in promoting or inhibiting aspects of the angiogenic process. The following description will therefore be useful in the practice of the invention.

With respect to the angiopoietins or other polypeptides used to practice the invention, it will be understood that native sequences will usually be most preferred, but that modifications can be made to most protein sequences without destroying the activity of interest of the protein, especially conservative amino acid substitions. By "conservative amino acid substitution" is meant substitution of an amino acid with an amino acid having a side chain of a similar chemical character. Similar amino acids for making conservative substitutions include those having an acidic side chain (glutamic acid, aspartic acid); a basic side chain (arginine, lysine, histidine); a polar amide side chain (glutamine, asparagine); a hydrophobic, aliphatic side chain (leucine, isoleucine, valine, alanine, glycine); an aromatic side chain (phenylalanine, tryptophan, tyrosine); a small side chain (glycine, alanine, serine, threonine, methionine); or an aliphatic hydroxyl side chain (serine, threonine).

Moreover, deletion and addition of amino acids is often possible without destroying a desired activity. With respect to the present invention, where binding activity is of particular interest and the ability of molecules to activate or inhibit receptor tyrosine kinases upon binding is of special interest, binding assays and tyrosine phophorylation assays are available to determine whether a particular ligand or ligand variant (a) binds and (b) stimulates or inhibits RTK activity.

Two manners for defining genera of polypeptide variants include percent amino acid identity to a native polypeptide (e.g., 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity preferred), or the ability of encoding-polynucleotides to hybridize to each other under specified conditions. One exemplary set of conditions is as follows: hybridization at 42°C in 50% formamide, 5X SSC, 20 mM Na•PO4, pH 6.8; and washing in 1X SSC at 55°C for 30 minutes. Formula for calculating equivalent hybridization conditions and/or selecting other conditions to achive a desired level of stringency are well known. It is understood in the art that conditions of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described Ausubel, et al. (Eds.), Protocols in Molecular

Biology, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe. The hybridization conditions can be calculated as described in Sambrook, et al., (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989), pp. 9.47 to 9.51.

B. Gene Therapy

While much of the application, including the examples, are written in the context of protein-protein interactions and protein administration, it should be clear that genetic manipulations to achieve modulation of protein expression or activity is specifically contemplated. For example, where administration of proteins is contemplated, administration of a gene therapy vector to cause the protein of interest to be produced in vivo also is contemplated. Where inhibition of proteins is contemplated (e.g., though use of antibodies or small molecule inhibitors), inhibition of protein expression in vivo by genetic techniques, such as knock-out techniques or interfering RNA or anti-sense therapy, is contemplated.

Any suitable vector may be used to introduce a transgene of interest into an animal. Exemplary vectors that have been described in the literature include replication-deficient retroviral vectors, including but not limited to lentivirus vectors [Kim et al., J. Virol., 72(1): 811-816 (1998); Kingsman & Johnson, Scrip Magazine, October, 1998, pp. 43-46.]; adeno-associated viral vectors [Gnatenko et al., J. Investig. Med., 45: 87-98 (1997)]; adenoviral vectors [See, e.g., U.S. Patent No. 5,792,453; Quantin et al., Proc. Natl. Acad. Sci. USA, 89: 2581-2584 (1992); Stratford-Perricadet et al., J. Clin. Invest., 90: 626-630 (1992); and Rosenfeld et al., Cell, 68: 143-155 (1992)]; Lipofectin-mediated gene transfer (BRL); liposomal vectors [See, e.g., U.S. Patent No. 5,631,237 (Liposomes comprising Sendai virus proteins)] ; and combinations thereof. All of the foregoing documents are incorporated herein by reference in the entirety. Replication-deficient adenoviral vectors and adeno-associated viral vectors constitute preferred embodiments.

In embodiments employing a viral vector, preferred polynucleotides include a suitable promoter and polyadenylation sequence to promote expression in

the target tissue of interest. For many applications of the present invention, the Tie promoter (U.S. Patent No. 5,877,020, incorporated by reference) will be especially suitable. Other suitable promoters/enhancers for mammalian cell expression include, e.g., cytomegalovirus promoter/enhancer [Lehner et al., J. Clin. Microbiol., 29:2494-2502 (1991); Boshart et al., Cell, 41:521-530 (1985)]; Rous sarcoma virus promoter [Davis et al., Hum. Gene Ther., 4:151 (1993)]; or simian virus 40 promoter.

Anti-sense polynucleotides are polynucleotides which recognize and hybridize to polynucleotides encoding a protein of interest and can therefore inhibit transcription or translation of the protein. Full length and fragment anti sense polynucleotides may be employed. Commercial software is available to optimize antisense sequence selection and also to compare selected sequences to known genomic sequences to help ensure uniqueness/specificity for a chosen gene. Such uniqueness can be further confirmed by hybridization analyses. Antisense nucleic acids (preferably 10 to 20 base pair oligonucleotides) are introduced into cells (e.g., by a viral vector or colloidal dispersion system such as a liposome). The antisense nucleic acid binds to the target nucleotide sequence in the cell and prevents transcription or translation of the target sequence. Phosphorothioate and methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use by the invention. The antisense oligonucleotides may be further modified by poly-L-lysine, transferrin polylysine, or cholesterol moieties at their 5′ end.

Genetic control can also be achieved through the design of novel transcription factors for modulating expression of the gene of interest in native cells and animals. For example, the Cys2-His2 zinc finger proteins, which bind DNA via their zinc finger domains, have been shown to be amenable to structural changes that lead to the recognition of different target sequences. These artificial zinc finger proteins recognize specific target sites with high affinity and low dissociation constants, and are able to act as gene switches to modulate gene expression. Knowledge of the particular target sequence of the present invention facilitates the engineering of zinc finger proteins specific for the target sequence using known methods such as a combination of structure-based modeling and screening of phage display libraries [Segal et al., (1999) Proc Natl Acad Sci USA 96:2758-2763; Liu et

al., (1997) Proc Natl Acad Sci USA 94:5525-30; Greisman and Pabo (1997) Science 275:657-61; Choo et al., (1997) J Mol Biol 273:525-32]. Each zinc finger domain usually recognizes three or more base pairs. Since a recognition sequence of 18 base pairs is generally sufficient in length to render it unique in any known genome, a zinc finger protein consisting of 6 tandem repeats of zinc fingers would be expected to ensure specificity for a particular sequence [Segal et al., (1999) Proc Natl Acad Sci USA 96:2758-2763]. The artificial zinc finger repeats, designed based on target sequences, are fused to activation or repression domains to promote or suppress gene expression [Liu et al., (1997) Proc Natl Acad Sci USA 94:5525-30]. Alternatively, the zinc finger domains can be fused to the TATA box-binding factor (TBP) with varying lengths of linker region between the zinc finger peptide and the TBP to create either transcriptional activators or repressors [Kim et al., (1997) Proc Natl Acad Sci USA 94:3616-3620]. Such proteins, and polynucleotides that encode them, have utility for modulating expression in vivo in both native cells, animals and humans. The novel transcription factor can be delivered to the target cells by transfecting constructs that express the transcription factor (gene therapy), or by introducing the protein. Engineered zinc finger proteins can also be designed to bind RNA sequences for use in therapeutics as alternatives to antisense or catalytic RNA methods [McColl et al., (1999) Proc Natl Acad Sci USA 96:9521-6; Wu et al., (1995) Proc Natl Acad Sci USA 92:344-348].

Another class of therapeutics for inhibiting expression (and therefore activity) of target genes/pathways described herein is interfering RNA technology, also known as RNA interference (RNAi) or short interfering RNA (siRNA).

Using the knowledge of the sequence of target genes such as Tie-1, Tie-2 and Ang-1, siRNA molecules are formed that interfere with the expression of the genes. SiRNA describes a technique by which post-transcriptional gene silencing (PTGS) is induced by the direct introduction of double stranded RNA (dsRNA: a mixture of both sense and antisense strands). (Fire et al., Nature 391:806-811, 1998). Current models of PTGS indicate that short stretches of interfering dsRNAs (21-23 nucleotides; siRNA also known as "guide RNAs") mediate PTGS. siRNAs are apparently produced by cleavage of dsRNA introduced directly or via a transgene or virus. These siRNAs may be amplified by an RNA-dependent RNA polymerase

(RdRP) and are incorporated into the RNA-induced silencing complex (RISC), guiding the complex to the homologous endogenous mRNA, where the complex cleaves the transcript. It is contemplated that RNAi may be used to disrupt the expression of a gene in a tissue-specific manner. By placing a gene fragment encoding the desired dsRNA behind an inducible or tissue-specific promoter, it should be possible to inactivate genes at a particular location within an organism or during a particular stage of development.

In one aspect, the invention provides double-stranded RNA (dsRNA) wherein one strand is complementary to a target region in a target Ang-1, Tie-1 or Tie-2 encoding polynucleotide. In general, dsRNA molecules of this type less than 30 nucleotides in length are referred to in the art as short interfering RNA (siRNA). The invention also contemplates, however, use of dsRNA molecules longer than 30 nucleotides in length, and in certain aspects of the invention, these longer dsRNA molecules can be about 30 nucleotides in length up to 200 nucleotides in length and longer, and including all length dsRNA molecules in between. As with other RNA inhibitors, complementarity of one strand in the dsRNA molecule can be a perfect match with the target region in the target polynucleotide, or may include mismatches to the extent that the mismatches do not preclude specific hybridization to the target region in the target Ang-1, Tie-1 or Tie-2 encoding polynucleotide. As with other RNA inhibition technologies, dsRNA molecules include those comprising modified internucleotide linkages and/or those comprising modified nucleotides which are known in the art to improve stability of the oligonucleotide, i.e., make the oligonucleotide more resistant to nuclease degradation, particularly in vivo. Preparation and use of RNAi compounds is described in U.S. Patent Application No. 20040023390, the disclosure of which is incorporated herein by reference in its entirety.

The invention further contemplates methods wherein inhibition of Ang-1, Tie-1 or Tie-2 is effected using RNA lasso technology. Circular RNA lasso inhibitors are highly structured molecules that are inherently more resistant to degradation and therefore do not, in general, include or require modified internucleotide linkage or modified nucleotides. The circular lasso structure includes a region that is capable of hybridizing to a target region in a target polynucleotide, the

hybridizing region in the lasso being of a length typical for other RNA inhibiting technologies. As with other RNA inhibiting technologies, the hybridizing region in the lasso may be a perfect match with the target region in the target polynucleotide, or may include mismatches to the extent that the mismatches do not preclude specific hybridization to the target region in the target PDGF-B or PDGFR-β-encoding polynucleotide. Because RNA lassos are circular and form tight topological linkage with the target region, inhibitors of this type are generally not displaced by helicase action unlike typical antisense oligonucleotides, and therefore can be utilized as dosages lower than typical antisense oligonucleotides. Preparation and use of RNA lassos is described in U.S. Patent 6,369,038, the disclosure of which is incorporated herein by reference in its entirety.

Anti-sense RNA and DNA molecules, ribozymes, RNAi and triple helix molecules directed against Ang-1, Tie-1 or Tie-2 can be prepared by any method known in the art for the synthesis of DNA and RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art including, but not limited to, solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably or transiently into cells.

C. Aptamer Therapeutics

Aptamers are another nucleic acid based method for interfering with Tie/Ang interaction is the use of an aptamer. Aptamers are DNA or RNA molecules that have been selected from random pools based on their ability to bind other molecules. Aptamers have been selected which bind nucleic acid, proteins, small organic compounds, and even entire organisms. Methods and compositions for identifying and making aptamers are known to those of skill in the art and are described e.g., in U.S. Patent No. 5,840,867 and U.S. Patent No. 5,582,981 each incorporated herein by reference. Aptamers that bind Tie or Ang are known to those

of skill in the art and are specifically contemplated to be useful in the present therapeutic embodiments.

Recent advances in the field of combinatorial sciences have identified short polymer sequences with high affinity and specificity to a given target. For example, SELEX technology has been used to identify DNA and RNA aptamers with binding properties that rival mammalian antibodies, the field of immunology has generated and isolated antibodies or antibody fragments which bind to a myriad of compounds and phage display has been utilized to discover new peptide sequences with very favorable binding properties. Based on the success of these molecular evolution techniques, it is certain that molecules can be created which bind to any target molecule. A loop structure is often involved with providing the desired binding attributes as in the case of: aptamers which often utilize hairpin loops created from short regions without complimentary base pairing, naturally derived antibodies that utilize combinatorial arrangement of looped hyper-variable regions and new phage display libraries utilizing cyclic peptides that have shown improved results when compared to linear peptide phage display results. Thus, sufficient evidence has been generated to suggest that high affinity ligands can be created and identified by combinatorial molecular evolution techniques. For the present invention, molecular evolution techniques can be used to isolate binding constructs specific for ligands described herein. For more on aptamers, See generally, Gold, L., Singer, B., He, Y.Y., Brody. E., "Aptamers As Therapeutic And Diagnostic Agents," J. Biotechnol. 74:5-13 (2000). Relevant techniques for generating aptamers may be found in U.S. Pat. No. 6,699,843, which is incorporated by reference in its entirety.

In some embodiments, the aptamer may be generated by preparing a library of nucleic acids; contacting the library of nucleic acids with a growth factor, wherein nucleic acids having greater binding affinity for the growth factor (relative to other library nucleic acids) are selected and amplified to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to the growth factor. The processes may be repeated, and the selected nucleic acids mutated and re-screened, whereby a growth factor aptamer is be identified.

D. Antibodies

Antibodies are useful for modulating Tie/Ang interactions due to the ability to easily generate antibodies with relative specificity, and due to the continued improvements in technologies for adopting antibodies to human therapy. Thus, the invention contemplates use of antibodies (e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementary determining region (CDR) grafted antibodies, including compounds which include CDR sequences which specifically recognize a polypeptide of the invention) specific for polypeptides of interest to the invention, especially Tie receptors and angiopoietins. Preferred antibodies are human antibodies which are produced and identified according to methods described in WO93/11236, published June 20, 1993, which is incorporated herein by reference in its entirety. Antibody fragments, including Fab, Fab', F(ab')2, and Fv, are also provided by the invention. The term "specific for," when used to describe antibodies of the invention, indicates that the variable regions of the antibodies of the invention recognize and bind the polypeptide of interest preferentially and substantially exclusively (i.e., able to distinguish the polypeptides of interest from other known polypeptides of the same family, by virtue of measurable differences in binding affinity, despite the possible existence of localized sequence identity, homology, or similarity between family members). It will be understood that specific antibodies may also interact with other proteins (for example, S. aureus protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow et al. (Eds), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor , NY (1988), Chapter 6. Antibodies of the invention can be produced using any method well known and routinely practiced in the art.

A monoclonal antibody to a Tie or angiopoietin protein may be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Köhler et al., (Nature, 256: 495-497, 1975), and the more recent human B-cell hybridoma technique (Kosbor et al.,

Immunology Today, 4: 72, 1983) and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R Liss, Inc., pp. 77-96, 1985), all specifically incorporated herein by reference. Antibodies also may be produced in bacteria from cloned immunoglobulin cDNAs. With the use of the recombinant phage antibody system it may be possible to quickly produce and select antibodies in bacterial cultures and to genetically manipulate their structure.

When the hybridoma technique is employed, myeloma cell lines may be used. Such cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and exhibit enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas). For example, where the immunized animal is a mouse, one may use P3-X63/Ag8, P3-X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bul; for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 all may be useful in connection with cell fusions.

Antibody fragments that contain the idiotype of the molecule may be generated by known techniques. For example, such fragments include, but are not limited to, the F(ab')2 fragment which may be produced by pepsin digestion of the antibody molecule; the Fab' fragments which may be generated by reducing the disulfide bridges of the F(ab')2 fragment, and the two Fab fragments which may be generated by treating the antibody molecule with papain and a reducing agent.

Non-human antibodies may be humanized by any methods known in the art. A preferred "humanized antibody" has a human constant region, while the variable region, or at least a complementarity determining region (CDR), of the antibody is derived from a non-human species. The human light chain constant region may be from either a kappa or lambda light chain, while the human heavy chain constant region may be from either an IgM, an IgG (IgG1, IgG2, IgG3, or IgG4) an IgD, an IgA, or an IgE immunoglobulin.

Methods for humanizing non-human antibodies are well known in the art (see U.S. Patent Nos. 5,585,089, and 5,693,762). Generally, a humanized antibody

has one or more amino acid residues introduced into its framework region from a source which is non-human. Humanization can be performed, for example, using methods described in Jones et al. (Nature 321: 522-525, 1986), Riechmann et al., (Nature, 332: 323-327, 1988) and Verhoeyen et al. Science 239:1534-1536, 1988), by substituting at least a portion of a rodent complementarity-determining region (CDRs) for the corresponding regions of a human antibody. Numerous techniques for preparing engineered antibodies are described, e.g., in Owens and Young, J. Immunol. Meth., 168:149 165, 1994. Further changes can then be introduced into the antibody framework to modulate affinity or immunogenicity.

E. Dosing

Polypeptides according to the invention may be administered in any suitable manner using an appropriate pharmaceutically-acceptable vehicle, e.g., a pharmaceutically-acceptable diluent, adjuvant, excipient or carrier. The composition to be administered according to methods of the invention preferably comprises (in addition to the polynucleotide or vector) a pharmaceutically-acceptable carrier solution such as water, saline, phosphate-buffered saline, glucose, or other carriers conventionally used to deliver therapeutics.

The "administering" that is performed according to the present invention may be performed using any medically-accepted means for introducing a therapeutic directly or indirectly into a mammalian subject, including but not limited to injections (e.g., intravenous, intramuscular, subcutaneous, or catheter); vaginal administration; oral ingestion; intranasal or topical administration; and the like. The therapeutic composition may be delivered to the patient at multiple sites. The multiple administrations may be rendered simultaneously or may be administered over a period of several hours. In certain cases it may be beneficial to provide a continuous flow of the therapeutic composition. Additional therapy may be administered on a period basis, for example, daily, weekly or monthly, although administration following ovulation is preferred.

Polypeptides for administration may be formulated with uptake or absorption enhancers to increase their efficacy. Such enhancer include for example, salicylate, glycocholate/linoleate, glycholate, aprotinin, bacitracin, SDS caprate and

the like. See, e.g., Fix (J. Pharm. Sci., 85(12) 1282-1285, 1996) and Oliyai and Stella (Ann. Rev. Pharmacol. Toxicol., 32:521-544, 1993).

The amounts of peptides in a given dosage will vary according to the size of the individual to whom the therapy is being administered as well as the serum half life and potency of the agent. A medicament may be administered as a single dosage form or as multiple doses. Standard dose-response studies, first in animal models such as mice or rats and then primates and then in clinical testing, reveal optimal dosages.

F. Kits

As an additional aspect, the invention includes kits which comprise compounds or compositions of the invention packaged in a manner which facilitates their use to practice methods of the invention. In a simplest embodiment, such a kit includes a compound or composition described herein as useful for practice of a method of the invention (e.g., polynucleotides or polypeptides for administration to a person), packaged in a container such as a sealed bottle or vessel, with a label affixed to the container or included in the package that describes use of the compound or composition to practice the method of the invention. Preferably, the compound or composition is packaged in a unit dosage form. The kit may further include a device suitable for administering the composition according to a preferred route of administration.

Compounds of compositions of the invention also may be packaged with or in admixture with other materials and methods for modulating female fertility, such as natural or synthetic hormones, including but not limited to ethinyl estradiol (EE), estrane progestins, levnorgestrels, and the like.

Additional aspects and details of the invention will be apparent from the following examples, which are intended to be illustrative rather than limiting.

EXAMPLE 1

In order to clarify the function of Tie-1 a mouse line was generated, which expresses an extracellular domain of human Tie-1 (tyrosine kinase with Ig and EGF homology domains 1) receptor fused to the human IgG Fc region under the K14 promoter in dermal keratinocytes. Expression of this construct *in vivo* is expected to result in the secretion of the soluble receptor molecule into the dermis and diffusion eventually into the blood stream and various tissue fluids where it would be able to trap possible ligand molecules and prevent their interaction with the endogenous receptor. Three different founder lines were used. The K14-Tie-1/Fc mice in FVB/N background were viable and appeared normal. However, while breeding this transgenic mouse line it became evident that the females were unable to produce progeny and the transgene was transferred to the next generation only via the males. Transgenic females from two different founder lines were mated with a transgenic male seven times. Each time, a plug was observed, but in only one of the females two embryos were found at E18.5, while no progeny was produced in the six matings. In contrast, when a transgenic male was mated with a FVB/N female, each of the fifteen mating resulted with a normal size litter (between 6 and 12 pups/litter, female:male ratio about 50:50).

To define the problem leading to infertility of the females, implantation of the embryo was studied. To this end, both transgenic and normal FVB/N females were super-ovulated and mated with normal FVB/N males. At E7.5 the animals were sacrificed and utero were removed for histological analysis. Embryos had implanted and appeared normal in both transgenic and non-transgenic utero, indicating that implantation takes places normally in these mice. However, no signs of the embryos were observed at E12.5.

When analyzing the ovaries after the super-ovulation, an abnormal luteinization in the transgenic animals was observed, which was not seen in the normal FVBN females. In addition, cyst formation was detected in the ovaries. Furthermore, the uterus had cyst formation surrounded by thin endometrium.

The expression of the soluble Tie-1 receptor under the K14 promoter in the skin of transgenic mice resulted in infertility of the females. The mice appeared otherwise normal, and the males were fertile and able to transfer the transgene to the next generation. Also, the same transgenic males, when mated with transgenic

females and producing no progeny, were able to produce normal progeny with normal FVB/N females indicating problems with the female mice. The ovaries showed massive luteinization with some maturing follicles of fairly normal appearance. However, the number of follicles seemed to be somewhat decreased compared to the wild type ovaries. It seems that the implantation of the embryos occurred subnormally; there were fewer implanted embryos in the transgenic utero than in the normal utero. No embryos were detected at E12.5, indicating problems in the post-implantation events. These observations also suggest that the sperm was not defective. Because the transgene expression in the embryos starts between E14 and E15, i.e., after the abortion of the transgenic progeny, and because not only the transgenic embryos get aborted, these results indicate that the infertility is due to the transgene expression in the mother.

Tie-1 and Tie-2 have been shown to form heterodimers as described below in Example 2 and in (Marron et al., 2000). No ligand has been reported for Tie-1, and none of the Tie-2 ligands are reported to bind directly to Tie-1, although, curiously, Tie-1 is phosphorylated upon Ang-1 or Ang-4 stimulation, as described below in Example 2. However, Ang-2 expression is readily detectable only in ovary, placenta, and uterus, which are the predominant sites of vascular remodeling in the normal adult, and the site where we see a phenotype in K14-Tie-1/Fc animals. Furthermore, Ang-2 mRNA expression is highly upregulated in the aged corpus luteum in which blood vessels degenerate. It is plausible that even if there is no direct binding of the angiopoietins to Tie-1, there exist a Tie-1/Tie-2 complex, which generates specific signals in the presence of Ang-2 and/or Ang-1. We are proposing a model in which the overexpression of the soluble Tie-1 receptor in the transgenic animals results in the abolishment of the signaling through endogenous Tie-1 receptor leading to sustained corpus luteum in the ovaries. The massive luteinization of the ovaries supports this idea and that probably leads to improper hormone production by the ovaries. The phenotype is very similar to that obtained in a transgenic mouse overexpressing the human chorionic gonadotropin, which also causes infertility of the females (Rulli et al., 2002). Furthermore, the placentation of the embryos could be defective in these transgenic animals.

Administration of a soluble Tie-1 extracellular domain construct (or the *in vivo* expression of same via gene therapy) in wildtype female adult mice can be performed to rule out the possibility that the presence of the soluble Tie-1 receptor would lead to defective development of the ovaries/uterus in the transgenic mice.

Results with the K14-Tie1/Fc transgenic mice indicate that blocking the signaling through Tie-1 receptor caused infertility in females, which indicates that soluble Tie1 has an indication as a contraceptive agent. The molecular mechanisms underlying this phenomenon also will be used to enhance fertility.

EXAMPLE 2

Tie-1 Interactions with Tie-2 and Angiopoietins

Experiments were conducted to evaluate and characterize Tie-1 interactions with Tie-2 and with angiopoietin family members. The results, summarized herein, are described in greater detail in Saharinen et al., 2005, J. Cell Biol., 169(2): 239-43, incorporated herein by reference in its entirety.

Materials and methods

293, 293T (American Type Culture Collection), and EA.hy926 immortalized hybrid HUVECs (Edgell et al., 1983) were grown in DME supplemented with 10% FBS (PromoCell). HUVECs were cultured as described in (Marron et al., 2000, J. Biol. Chem., 275: 39741–39746). LEC, BEC (Makinen et al., 2001, EMBO J., 20: 4762–4773), and HMEC-1 human dermal microvascular cells immortalized with SV40 Large T antigen (Ades et al., 1992, J. Invest. Dermatol., 99: 683–690) were grown in Endothelial Cell Basal Medium (PromoCell) with supplements provided by the manufacturer. Confluent plates of cells were serum-starved overnight, followed by ligand stimulation for 15 minutes, unless otherwise indicated.

The following reagents were used: Tie-1-Fc, Tie-2-Fc, Ang-1, VEGF (all from R&D Systems), Ang-2, Ang-3, Ang-4 (Lee et al., FASEB J., 18: 1200–

1208.2004), COMP-HFARP (Kim et al., 2000, Biochem. J., 346:603–610), and Ang-2 (Scharpfenecker et al., 2005, J. Cell Sci., 188:771–780).

The following antibodies were used: antiphosphotyrosine (4G10; Upstate Biotechnology), anti-Tie-1 and anti-Tie-2 (R&D Systems; Santa Cruz Biotechnology, Inc.; clone 33 [Upstate Biotechnology]), anti-V5 (Invitrogen), and anti-Tie-2 (Harris et al., 2001, Clin. Cancer Res., 7: 1992–1997).

Cells were transfected using Fugene6 (Roche Diagnostics), changed to serum-free medium after 48 hours, and harvested 72 hours after transfection. Kinase-inactivating mutation in human Tie-2 (lysine 855 to arginine), human Tie-1 (lysine 870 to arginine), Tie1-V5, and Tie2-Myc constructs were created by PCR. All constructs were confirmed by sequencing (Applied Biosystems).

For immunoprecipitation and immunoblotting, cells were lysed in lysis buffer (50 mM Hepes, pH 7.5, 1% Triton X-100, 5% glycerol, 1 mM EGTA, 150 mM NaCl, 1.5 mM MgCl2, 100 mM NaF, 1 mM Na3VO4, PMSF, aprotinin, and leupeptin) or alternatively in SDS-lysis buffer (Saharinen et al., 1997, Blood, 90: 4341–4353). Equal amounts of cell lysate protein were pre-cleared by incubation with protein G–Sepharose (Amersham Biosciences), followed by addition of BSA (1%) and specific antibodies. The immunocomplexes, captured by protein G–Sepharose, were separated in 7.5% SDS-PAGE (Ready-Gels; Bio-Rad Laboratories) and blotted and detected using specific primary antibodies, biotinylated anti–mouse or anti–goat secondary antibodies (DakoCytomation), and streptavidinbiotin HRP conjugate (Amersham Biosciences) followed by ECL detection with the SuperSignal West Femto Maximun Sensitivity Substrate (Pierce Chemical Co.).

HUVECs were cross-linked in PBS containing 0.5 mM DTSSP for 30 minutes, quenched by addition of Tris, pH 7.5, to 100 mM, and lysed in 50 mM Tris, pH 7.4, 50 mM NaCl, 1% Triton X-100, 1mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM EGTA, and complete protease inhibitor.

293T cells were cross-linked for 40 min with 1 mM DTSSP on ice.

For RNA isolation and Northern blotting, total RNA was isolated using the RNeasy kit (QIAGEN), electrophoresed, blotted, and hybridized with 32P-labeled cDNA probes.

Results

To investigate the signal transduction pathways of Tie-1, human dermal blood vascular endothelial cells (BEC) and lymphatic endothelial cells (LEC; Makinen et al., 2001, EMBO J., 20: 4762–4773) were stimulated with a COMP-Ang-1 chimeric protein (Cho et al., 2004, Proc. Natl. Acad. Sci. USA., 101: 5547–5552; Cho et al., 2004, Proc. Natl. Acad. Sci. USA., 101: 5553–5558, both incorportated herein by reference).

Surprisingly, COMP-Ang-1 induced tyrosine phosphorylation of Tie-1, in addition to phosphorylation of Tie-2. Phosphorylation of Tie-1 occurred in endothelial cells within 5 minutes of COMP-Ang-1 stimulation, reaching a maximum level at 1 hour, followed by a gradual down-regulation. The kinetics of Tie-2 phosphorylation paralleled these changes observed for Tie-1. Significant phosphorylation occurred with a 100 ng/ml concentration of COMP-Ang-1, but maximal phosphorylation of both receptors required 600 ng/ml. COMP-Ang-1 also induced phosphorylation of Tie-1 and Tie-2 in the hybrid endothelial cell line EA.hy926.

In contrast, 600 ng/ml Ang-2 did not activate either Tie-1 or Tie-2. In fact, decreased Tie-1 phosphorylation was seen when COMP-Ang-1 was provided in combination with an excess of Ang-2.

The soluble extracellular domain of Tie-2 (Tie-2-Fc) has been found to bind Ang-1 and to inhibit Ang-1-induced Tie-2 activation, whereas no effect has been found with the soluble Tie-1 receptor (Davis et al., 1996; Peters et al., 2004). Tie-2-Fc inhibited COMP-Ang-1–induced Tie-1 and Tie-2 phosphorylation, whereas Tie-1-Fc had little if any effect, indicating that COMP-Ang-1 binds to the soluble form of Tie-2 but not to soluble Tie-1, although COMP-Ang-1 was capable of inducing activation of Tie-1 at the cell surface.

To understand the mechanism of COMP-Ang-1–induced Tie-1 activation, Tie-1 was over-expressed in 293T cells, which lack both Tie-1 and Tie-2. Variable and low levels of Tie-1 tyrosine phosphorylation were detected after stimulation of these cells with 600 ng/ml of COMP-Ang-1. This finding suggested that over-expressed Tie-1 can be activated to some degree by high concentrations of COMP-Ang-1 in the absence of Tie-2.

The effect of Tie-2 on COMP-Ang-1 activation of Tie-1 in the transfected cells was examined. Because of the strong basal autophosphorylation of Tie-2 observed in 293T cells, 293 cells that do not replicate transiently transfected expression plasmids were used. The 293 cells were transfected with vectors encoding Tie-1, Tie-2, or both receptors, and stimulated with COMP-Ang-1. COMP-Ang-1–induced tyrosine phosphorylation of Tie-1 was increased in the double transfected cells in comparison with cells transfected only with Tie-1, suggesting that heteromerization of Tie-1 and Tie-2 enhances Tie-1 activation. In contrast, Tie-2 phosphorylation was not enhanced by the presence of Tie-1 when compared with cells transfected with Tie-2 alone.

It was possible that Tie-2 was required for high-affinity binding of COMP-Ang-1 to Tie-1, or that Tie-2 induced the phosphorylation and thereby enhanced the activation of Tie-1 in a Tie-1–Tie-2 complex. To analyze this hypothesis, K870R-Tie-1 was expressed with or without Tie-2. This Tie-1 variant has an inactivating substitution in the kinase domain. K870R-Tie-1 was phosphorylated in a ligand-dependent manner when coexpressed with Tie-2, whereas no phosphorylation was detected in the absence of Tie-2. Thus, Tie-2 was able to induce Tie-1 phosphorylation.

A kinase-inactive K855R-Tie-2 was tested to determine if it, like wild-type Tie-2, was able to enhance Tie-1 phosphorylation. Tie-1 phosphorylation was reduced when it was co-expressed with K855R-Tie-2, indicating that the kinase activity of Tie-2 is required for full enhancement of Tie-1 activation by COMP-Ang-1.

The results obtained from the transfected cells suggested that Tie-1 and Tie-2 undergo heteromerization when stimulated by COMP-Ang-1. To analyze this

finding, 293T cells transfected with Tie-1-V5 and Tie-2-Myc constructs were used. After COMP-Ang-1 stimulation, the cell surface proteins were chemically cross-linked with 3,3'-dithiobis[sulfosuccinimidylpropionate] (DTSSP), a membrane non-permeable cross-linker, and Tie-1 was immunoprecipitated from the cell lysates. Interestingly, Tie-2 was co-precipitated with Tie-1 from the double transfected cells. The treatment of human umbilical vein endothelial cells (HUVECs) with DTSSP resulted in co-precipitation of Tie-1 with Tie-2, whereas no co-precipitation was found in non-treated cells. This evidence indidates that Tie-1 and Tie-2 form heteromeric complexes on the cell surface.

These results also suggest that, in the heteromeric complexes, Tie-2 directly phosphorylates Tie-1, as Tie-2 induced phosphorylation of kinase-inactive Tie-1 in a COMPAng-1–dependent manner. COMP-Ang-1 has been shown to be a more potent angiopoietin ligand than native Ang-1 (Cho et al., 2004).

Experiments also were conducted to analyze whether native Ang-1 can induce Tie-1 phosphorylation. Native Ang-1 induced Tie-1 phosphorylation in endothelial cells, although several-fold less efficiently than COMP-Ang-1. The chimeric protein COMP-HFARP (hepatic fibrinogen/angiopoietin-related protein) that does not bind to Tie-1 or Tie-2 (Kim et al., 2000) had no effect even at high concentrations. Thus, COMP-Ang-1–induced Tie-1 activation is mediated via Ang-1 and not by the COMP domain. In addition to Ang-1, Ang-4 is a ligand for human Tie-2, whereas Ang-3 is a specific ligand for murine Tie-2 (Lee et al., 2004, FASEB J., 18:1200–1208.). In additional experiments, Tie-1 phosphorylation was induced by native Ang-4, but not by Ang-3 or Ang-2.

REFERENCES

Blumenthal, R. D., Taylor, A. P., Goldman, L., Brown, G., and Goldenberg, D. M. (2002). Abnormal expression of the angiopoietins and Tie receptors in menorrhagic endometrium. Fertil Steril *78*, 1294-1300.

Dumont, D. J., Gradwohl, G., Fong, G. H., Puri, M. C., Gertsenstein, M., Auerbach, A., and Breitman, M. L. (1994). Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev *8*, 1897-1909.

Ferrara, N., Gerber, H. P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat Med *9*, 669-676.

Gale, N. W., Thurston, G., Hackett, S. F., Renard, R., Wang, Q., McClain, J., Martin, C., Witte, C., Witte, M. H., Jackson, D., *et al.* (2002). Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell *3*, 411-423.

Kaipainen, A., Vlaykova, T., Hatva, E., Bohling, T., Jekunen, A., Pyrhonen, S., and Alitalo, K. (1994). Enhanced expression of the tie receptor tyrosine kinase mesenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res *54*, 6571-6577.

Korhonen, J., Partanen, J., Armstrong, E., Vaahtokari, A., Elenius, K., Jalkanen, M., and Alitalo, K. (1992). Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. Blood *80*, 2548-2555.

Korhonen, J., Polvi, A., Partanen, J., and Alitalo, K. (1994). The mouse tie receptor tyrosine kinase gene: expression during embryonic angiogenesis. Oncogene *9*, 395-403.

Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., *et al.* (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science *277*, 55-60.

Marron, M. B., Hughes, D. P., Edge, M. D., Forder, C. L., and Brindle, N. P. (2000). Evidence for heterotypic interaction between the receptor tyrosine kinases TIE-1 and TIE-2. J Biol Chem *275*, 39741-39746.

Partanen, J., Armstrong, E., Makela, T. P., Korhonen, J., Sandberg, M., Renkonen, R., Knuutila, S., Huebner, K., and Alitalo, K. (1992). A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol *12*, 1698-1707.

Puri, M. C., Partanen, J., Rossant, J., and Bernstein, A. (1999). Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development. Development *126*, 4569-4580.

Puri, M. C., Rossant, J., Alitalo, K., Bernstein, A., and Partanen, J. (1995). The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. Embo J *14*, 5884-5891.

Rossant, J., and Howard, L. (2002). Signaling pathways in vascular development. Annu Rev Cell Dev Biol *18*, 541-573.

Rulli, S. B., Kuorelahti, A., Karaer, O., Pelliniemi, L. J., Poutanen, M., and Huhtaniemi, I. (2002). Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin. Endocrinology *143*, 4084-4095.

Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., and Qin, Y. (1995). Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature *376*, 70-74.

Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., and Yancopoulos, G. D. (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell *87*, 1171-1180.

Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., and McDonald, D. M. (1999). Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science *286*, 2511-2514.

All documents cited herein are hereby incorporated by reference in their entirety.

The invention has been described with reference to specific embodiments and experiments. However, the foregoing description should be understood to be exemplary and not limiting. The only limitations defining or placed on the invention are those in the claims.

What is claimed is:

1. A method of modulating fertility or embryogenesis in a mammalian female, comprising:

administering to a mammalian female a medicament comprising a modulator of angiopoietin-induced Tie receptor activity in cells of the female, in an amount effective to modulate fertility or embryogenesis in the female.

2. Use of a modulator of angiopoietin-induced Tie receptor activity in the manufacture of a medicament to modulate fertility or embryogenesis in a mammalian female.

3. The method or use of claims 1 or 2, wherein the female is human.

4. The method or use of any one of claims 1-3, wherein the medicament further comprises a pharmaceutically acceptable diluent, excipient or carrier.

5. The method or use of any one of claims 1-4, wherein the modulator is an inhibitor of angiopoietin-induced Tie receptor activity, and the modulator is present in the medicament in an amount effective to inhibit fertility or embryogenesis.

6. The method or use of claim 5, wherein the inhibitor comprises a soluble polypeptide that binds to an angiopoietin protein and comprises an amino acid sequence that is at least 80% identical to the extracellular domain amino acid sequence of a mammalian Tie-1 or Tie-2 receptor tyrosine kinase.

7. The method or use of claim 5, wherein the inhibitor comprises a member selected from the group consisting of:

(A) a polypeptide that comprises:

(i) an amino acid sequence that is at least 80% identical to amino acids 25-759 of SEQ ID NO: 2;

(ii) an amino acid sequence that is at least 80% identical to amino acids 23-745 of SEQ ID NO: 4; and

(iii) fragments of (i) or (ii);

wherein the polypeptide binds at least one angiopoietin polypeptide selected from the group consisting of Angiopoietin-1 (SEQ ID NO: 6), Angiopoietin-2 (SEQ ID NO: 8), Angiopoietin-3 (SEQ ID NO: 10), and Angiopoietin-4 (SEQ ID NO: 12);

(B) polynucleotides that comprise a nucleotide sequence that encode a polypeptide according to (A); and

(C) vectors that comprise a polynucleotide according to (B).

8. A method or use according to claim 6 or 7, wherein the polypeptide further comprises an immunoglobulin Fc fragment.

9. The method or use according to claim 8, wherein the immunoglobulin Fc fragment comprises an IgG Fc domain.

10. The method or use according to claim 5, wherein the inhibitor comprises an antibody substance that specifically immunoreacts to the extracellular domain of a Tie-1 or Tie-2 receptor tyrosine kinase, wherein the antibody substance comprises: (a) a monoclonal or polyclonal antibody; (b) a fragment of (a) that retains said immunoreactivity; or (c) a polypeptide that comprises an antigen binding fragment of (a) and that retains said immunoreactivity.

11. The method according to claim 5, wherein the inhibitor comprises an interfering RNA that inhibits expression of a polypeptide selected from the group consisting of a Tie-1 receptor tyrosine kinase, a Tie-2 receptor tyrosine kinase; Angiopoietin-1, Angiopoietin-2, Angiopoietin-3, and Angiopoietin-4.

12. The method or use according to any one of claims 1-4, wherein the modulator is an agonist of Tie receptor activity, and is present in the medicament in an amount effective to increase fertility or promote embryogenesis in the female.

13. The method or use of claim 12, wherein the agonist comprises (a) a polypeptide that comprises an amino acid sequence at least 80% identical to a mammalian angiopoietin polypeptide or fragments thereof that is effective to bind and stimulate a Tie receptor tyrosine kinase; or (b) a polynucleotide that comprises a nucleotide sequence that encodes said polypeptide; or (c) a vector that comprises the polynucleotide.

14. The method or use according to claim 13, wherein the angiopoietin polypeptide is selected from group consisting of human angiopoietin-1 (SEQ ID NO: 6), angiopoietin-2 (SEQ ID NO: 8), angiopoietin-3 (SEQ ID NO: 10), and angiopoietin-4 (SEQ ID NO: 12).

15. The method or use according to any one of claims 1-14, wherein the medicament is administered orally, by intravenous injection, by intramuscular injection, or other injection, by transdermal patch, topically or vaginally.

16. The method according to any one of claims 1-14, wherein the medicament is administered after ovulation.

17. A method of screening for infertility in a female, comprising measuring Tie receptor expression or activity in a biological sample from a mammalian female, wherein Tie expression or activity correlates with fertility.

18. The method of claim 17, wherein the biological sample comprises primary cilia of ovarian surface endothelium.

19. A method of screening for modulators of binding between a Tie receptor tyrosine kinase and an angiopoietin ligand, comprising:

a) contacting a Tie receptor composition with an angiopoietin ligand in the presence and in the absence of a putative modulator compound;

b) measuring binding between the Tie receptor and the angiopoietin ligand in the presence and absence of the putative modulator compound; and

c) identifying a modulator compound based on a decrease or increase in said binding in the presence of the putative modulator compound, as compared to binding in the absence of the putative modulator compound.

20. A method according to claim 19, wherein the Tie receptor composition comprises a cell that expresses Tie-1 receptor on its surface.

21. A method according to claim 20, wherein the cell further expresses Tie-2 receptor on its surface.

22. A method according to any one of claims 19-21, further comprising a step of:

(d) making a modulator composition by formulating a modulator identified according to step (c) in a pharmaceutically acceptable carrier.

23. A method according to claim 22, further comprising a step of:

(e) administering the modulator composition to a mammal that comprises cells that express Tie receptors, and determining physiological effects of the modulator composition in the mammal.

24. A method according to claim 23, comprising assessing fertility in mammal.

25. A method according to any one of claims 19-24, wherein the Tie receptor is selected from the group consisting of a mammalian Tie-1 and a mammalian Tie-2 and mixtures thereof.

26. A method according to claim 25, wherein the Tie receptor and the angiopoietin are human.

SEQUENCE LISTING

<110> LICENTIA, LTD.

<120> Tie Receptor and Tie Ligand Materials and Methods for Modulating Female Fertility

<130> 3432P103WO

<150> US 60/582,858

<151> 2005-06-25

<160> 12

<170> PatentIn version 3.0

<210> 1

<211> 3845

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (37)..(3453)

<220>

<221> misc_feature

<223> Human Tie-1

<400> 1

```
cgctcgtcct ggctggcctg ggtcggcctc tggagt atg gtc tgg cgg gtg ccc        54
                                        Met Val Trp Arg Val Pro
                                        1               5

cct ttc ttg ctc ccc atc ctc ttc ttg gct tct cat gtg ggc gcg gcg       102
Pro Phe Leu Leu Pro Ile Leu Phe Leu Ala Ser His Val Gly Ala Ala
            10                  15                  20

gtg gac ctg acg ctg ctg gcc aac ctg cgg ctc acg gac ccc cag cgc       150
Val Asp Leu Thr Leu Leu Ala Asn Leu Arg Leu Thr Asp Pro Gln Arg
        25                  30                  35

ttc ttc ctg act tgc gtg tct ggg gag gcc ggg gcg ggg agg ggc tcg       198
```

```
Phe Phe Leu Thr Cys Val Ser Gly Glu Ala Gly Ala Gly Arg Gly Ser
    40                  45                  50

gac gcc tgg ggc ccg ccc ctg ctg ctg gag aag gac gac cgt atc gtg      246
Asp Ala Trp Gly Pro Pro Leu Leu Leu Glu Lys Asp Asp Arg Ile Val
55                  60                  65                  70

cgc acc ccg ccc ggg cca ccc ctg cgc ctg gcg cgc aac ggt tcg cac      294
Arg Thr Pro Pro Gly Pro Pro Leu Arg Leu Ala Arg Asn Gly Ser His
                75                  80                  85

cag gtc acg ctt cgc ggc ttc tcc aag ccc tcg gac ctc gtg ggc gtc      342
Gln Val Thr Leu Arg Gly Phe Ser Lys Pro Ser Asp Leu Val Gly Val
            90                  95                  100

ttc tcc tgc gtg ggc ggt gct ggg gcg cgg cgc acg cgc gtc atc tac      390
Phe Ser Cys Val Gly Gly Ala Gly Ala Arg Arg Thr Arg Val Ile Tyr
        105                 110                 115

gtg cac aac agc cct gga gcc cac ctg ctt cca gac aag gtc aca cac      438
Val His Asn Ser Pro Gly Ala His Leu Leu Pro Asp Lys Val Thr His
    120                 125                 130

act gtg aac aaa ggt gac acc gct gta ctt tct gca cgt gtg cac aag      486
Thr Val Asn Lys Gly Asp Thr Ala Val Leu Ser Ala Arg Val His Lys
135                 140                 145                 150

gag aag cag aca gac gtg atc tgg aag agc aac gga tcc tac ttc tac      534
Glu Lys Gln Thr Asp Val Ile Trp Lys Ser Asn Gly Ser Tyr Phe Tyr
                155                 160                 165

acc ctg gac tgg cat gaa gcc cag gat ggg cgg ttc ctg ctg cag ctc      582
Thr Leu Asp Trp His Glu Ala Gln Asp Gly Arg Phe Leu Leu Gln Leu
            170                 175                 180

cca aat gtg cag cca cca tcg agc ggc atc tac agt gcc act tac ctg      630
Pro Asn Val Gln Pro Pro Ser Ser Gly Ile Tyr Ser Ala Thr Tyr Leu
        185                 190                 195

gaa gcc agc ccc ctg ggc agc gcc ttc ttt cgg ctc atc gtg cgg ggt      678
Glu Ala Ser Pro Leu Gly Ser Ala Phe Phe Arg Leu Ile Val Arg Gly
    200                 205                 210

tgt ggg gct ggg cgc tgg ggg cca ggc tgt acc aag gag tgc cca ggt      726
Cys Gly Ala Gly Arg Trp Gly Pro Gly Cys Thr Lys Glu Cys Pro Gly
215                 220                 225                 230

tgc cta cat gga ggt gtc tgc cac gac cat gac ggc gaa tgt gta tgc      774
Cys Leu His Gly Gly Val Cys His Asp His Asp Gly Glu Cys Val Cys
                235                 240                 245

ccc cct ggc ttc act ggc acc cgc tgt gaa cag gcc tgc aga gag ggc      822
Pro Pro Gly Phe Thr Gly Thr Arg Cys Glu Gln Ala Cys Arg Glu Gly
            250                 255                 260

cgt ttt ggg cag agc tgc cag gag cag tgc cca ggc ata tca ggc tgc      870
Arg Phe Gly Gln Ser Cys Gln Glu Gln Cys Pro Gly Ile Ser Gly Cys
        265                 270                 275

cgg ggc ctc acc ttc tgc ctc cca gac ccc tat ggc tgc tct tgt gga      918
Arg Gly Leu Thr Phe Cys Leu Pro Asp Pro Tyr Gly Cys Ser Cys Gly
    280                 285                 290

tct ggc tgg aga gga agc cag tgc caa gaa gct tgt gcc cct ggt cat      966
Ser Gly Trp Arg Gly Ser Gln Cys Gln Glu Ala Cys Ala Pro Gly His
295                 300                 305                 310

ttt ggg gct gat tgc cga ctc cag tgc cag tgt cag aat ggt ggc act     1014
```

```
Phe Gly Ala Asp Cys Arg Leu Gln Cys Gln Cys Gln Asn Gly Gly Thr
                315                 320                 325

tgt gac cgg ttc agt ggt tgt gtc tgc ccc tct ggg tgg cat gga gtg     1062
Cys Asp Arg Phe Ser Gly Cys Val Cys Pro Ser Gly Trp His Gly Val
            330                 335                 340

cac tgt gag aag tca gac cgg atc ccc cag atc ctc aac atg gcc tca     1110
His Cys Glu Lys Ser Asp Arg Ile Pro Gln Ile Leu Asn Met Ala Ser
        345                 350                 355

gaa ctg gag ttc aac tta gag acg atg ccc cgg atc aac tgt gca gct     1158
Glu Leu Glu Phe Asn Leu Glu Thr Met Pro Arg Ile Asn Cys Ala Ala
    360                 365                 370

gca ggg aac ccc ttc ccc gtg cgg ggc agc ata gag cta cgc aag cca     1206
Ala Gly Asn Pro Phe Pro Val Arg Gly Ser Ile Glu Leu Arg Lys Pro
375                 380                 385                 390

gac ggc act gtg ctc ctg tcc acc aag gcc att gtg gag cca gag aag     1254
Asp Gly Thr Val Leu Leu Ser Thr Lys Ala Ile Val Glu Pro Glu Lys
                395                 400                 405

acc aca gct gag ttc gag gtg ccc cgc ttg gtt ctt gcg gac agt ggg     1302
Thr Thr Ala Glu Phe Glu Val Pro Arg Leu Val Leu Ala Asp Ser Gly
            410                 415                 420

ttc tgg gag tgc cgt gtg tcc aca tct ggc ggc caa gac agc cgg cgc     1350
Phe Trp Glu Cys Arg Val Ser Thr Ser Gly Gly Gln Asp Ser Arg Arg
        425                 430                 435

ttc aag gtc aat gtg aaa gtg ccc ccc gtg ccc ctg gct gca cct cgg     1398
Phe Lys Val Asn Val Lys Val Pro Pro Val Pro Leu Ala Ala Pro Arg
    440                 445                 450

ctc ctg acc aag cag agc cgc cag ctt gtg gtc tcc ccg ctg gtc tcg     1446
Leu Leu Thr Lys Gln Ser Arg Gln Leu Val Val Ser Pro Leu Val Ser
455                 460                 465                 470

ttc tct ggg gat gga ccc atc tcc act gtc cgc ctg cac tac cgg ccc     1494
Phe Ser Gly Asp Gly Pro Ile Ser Thr Val Arg Leu His Tyr Arg Pro
                475                 480                 485

cag gac agt acc atg gac tgg tcg acc att gtg gtg gac ccc agt gag     1542
Gln Asp Ser Thr Met Asp Trp Ser Thr Ile Val Val Asp Pro Ser Glu
            490                 495                 500

aac gtg acg tta atg aac ctg agg cca aag aca gga tac agt gtt cgt     1590
Asn Val Thr Leu Met Asn Leu Arg Pro Lys Thr Gly Tyr Ser Val Arg
        505                 510                 515

gtg cag ctg agc cgg cca ggg gaa gga gga gag ggg gcc tgg ggg cct     1638
Val Gln Leu Ser Arg Pro Gly Glu Gly Gly Glu Gly Ala Trp Gly Pro
    520                 525                 530

ccc acc ctc atg acc aca gac tgt cct gag cct ttg ttg cag ccg tgg     1686
Pro Thr Leu Met Thr Thr Asp Cys Pro Glu Pro Leu Leu Gln Pro Trp
535                 540                 545                 550

ttg gag ggc tgg cat gtg gaa ggc act gac cgg ctg cga gtg agc tgg     1734
Leu Glu Gly Trp His Val Glu Gly Thr Asp Arg Leu Arg Val Ser Trp
                555                 560                 565

tcc ttg ccc ttg gtg ccc ggg cca ctg gtg ggc gac ggt ttc ctg ctg     1782
Ser Leu Pro Leu Val Pro Gly Pro Leu Val Gly Asp Gly Phe Leu Leu
            570                 575                 580

cgc ctg tgg gac ggg aca cgg ggg cag gag cgg cgg gag aac gtc tca     1830
```

```
Arg Leu Trp Asp Gly Thr Arg Gly Gln Glu Arg Arg Glu Asn Val Ser
        585                 590                 595

tcc ccc cag gcc cgc act gcc ctc ctg acg gga ctc acg cct ggc acc     1878
Ser Pro Gln Ala Arg Thr Ala Leu Leu Thr Gly Leu Thr Pro Gly Thr
    600                 605                 610

cac tac cag ctg gat gtg cag ctc tac cac tgc acc ctc ctg ggc ccg     1926
His Tyr Gln Leu Asp Val Gln Leu Tyr His Cys Thr Leu Leu Gly Pro
615                 620                 625                 630

gcc tcg ccc cct gca cac gtg ctt ctg ccc ccc agt ggg cct cca gcc     1974
Ala Ser Pro Pro Ala His Val Leu Leu Pro Pro Ser Gly Pro Pro Ala
                635                 640                 645

ccc cga cac ctc cac gcc cag gcc ctc tca gac tcc gag atc cag ctg     2022
Pro Arg His Leu His Ala Gln Ala Leu Ser Asp Ser Glu Ile Gln Leu
            650                 655                 660

aca tgg aag cac ccg gag gct ctg cct ggg cca ata tcc aag tac gtt     2070
Thr Trp Lys His Pro Glu Ala Leu Pro Gly Pro Ile Ser Lys Tyr Val
        665                 670                 675

gtg gag gtg cag gtg gct ggg ggt gca gga gac cca ctg tgg ata gac     2118
Val Glu Val Gln Val Ala Gly Gly Ala Gly Asp Pro Leu Trp Ile Asp
    680                 685                 690

gtg gac agg cct gag gag aca agc acc atc atc cgt ggc ctc aac gcc     2166
Val Asp Arg Pro Glu Glu Thr Ser Thr Ile Ile Arg Gly Leu Asn Ala
695                 700                 705                 710

agc acg cgc tac ctc ttc cgc atg cgg gcc agc att cag ggg ctc ggg     2214
Ser Thr Arg Tyr Leu Phe Arg Met Arg Ala Ser Ile Gln Gly Leu Gly
                715                 720                 725

gac tgg agc aac aca gta gaa gag tcc acc ctg ggc aac ggg ctg cag     2262
Asp Trp Ser Asn Thr Val Glu Glu Ser Thr Leu Gly Asn Gly Leu Gln
            730                 735                 740

gct gag ggc cca gtc caa gag agc cgg gca gct gaa gag ggc ctg gat     2310
Ala Glu Gly Pro Val Gln Glu Ser Arg Ala Ala Glu Glu Gly Leu Asp
        745                 750                 755

cag cag ctg atc ctg gcg gtg gtg ggc tcc gtg tct gcc acc tgc ctc     2358
Gln Gln Leu Ile Leu Ala Val Val Gly Ser Val Ser Ala Thr Cys Leu
    760                 765                 770

acc atc ctg gcc gcc ctt tta acc ctg gtg tgc atc cgc aga agc tgc     2406
Thr Ile Leu Ala Ala Leu Leu Thr Leu Val Cys Ile Arg Arg Ser Cys
775                 780                 785                 790

ctg cat cgg aga cgc acc ttc acc tac cag tca ggc tcg ggc gag gag     2454
Leu His Arg Arg Arg Thr Phe Thr Tyr Gln Ser Gly Ser Gly Glu Glu
                795                 800                 805

acc atc ctg cag ttc agc tca ggg acc ttg aca ctt acc cgg cgg cca     2502
Thr Ile Leu Gln Phe Ser Ser Gly Thr Leu Thr Leu Thr Arg Arg Pro
            810                 815                 820

aaa ctg cag ccc gag ccc ctg agc tac cca gtg cta gag tgg gag gac     2550
Lys Leu Gln Pro Glu Pro Leu Ser Tyr Pro Val Leu Glu Trp Glu Asp
        825                 830                 835

atc acc ttt gag gac ctc atc ggg gag ggg aac ttc ggc cag gtc atc     2598
Ile Thr Phe Glu Asp Leu Ile Gly Glu Gly Asn Phe Gly Gln Val Ile
    840                 845                 850

cgg gcc atg atc aag aag gac ggg ctg aag atg aac gca gcc atc aaa     2646
```

```
Arg Ala Met Ile Lys Lys Asp Gly Leu Lys Met Asn Ala Ala Ile Lys
855                 860                 865                 870

atg ctg aaa gag tat gcc tct gaa aat gac cat cgt gac ttt gcg gga     2694
Met Leu Lys Glu Tyr Ala Ser Glu Asn Asp His Arg Asp Phe Ala Gly
                875                 880                 885

gaa ctg gaa gtt ctg tgc aaa ttg ggg cat cac ccc aac atc atc aac     2742
Glu Leu Glu Val Leu Cys Lys Leu Gly His His Pro Asn Ile Ile Asn
            890                 895                 900

ctc ctg ggg gcc tgt aag aac cga ggt tac ttg tat atc gct att gaa     2790
Leu Leu Gly Ala Cys Lys Asn Arg Gly Tyr Leu Tyr Ile Ala Ile Glu
        905                 910                 915

tat gcc ccc tac ggg aac ctg cta gat ttt ctg cgg aaa agc cgg gtc     2838
Tyr Ala Pro Tyr Gly Asn Leu Leu Asp Phe Leu Arg Lys Ser Arg Val
    920                 925                 930

cta gag act gac cca gct ttt gct cga gag cat ggg aca gcc tct acc     2886
Leu Glu Thr Asp Pro Ala Phe Ala Arg Glu His Gly Thr Ala Ser Thr
935                 940                 945                 950

ctt agc tcc cgg cag ctg ctg cgt ttc gcc agt gat gcg gcc aat ggc     2934
Leu Ser Ser Arg Gln Leu Leu Arg Phe Ala Ser Asp Ala Ala Asn Gly
                955                 960                 965

atg cag tac ctg agt gag aag cag ttc atc cac agg gac ctg gct gcc     2982
Met Gln Tyr Leu Ser Glu Lys Gln Phe Ile His Arg Asp Leu Ala Ala
            970                 975                 980

cgg aat gtg ctg gtc gga gag aac cta gcc tcc aag att gca gac ttc     3030
Arg Asn Val Leu Val Gly Glu Asn Leu Ala Ser Lys Ile Ala Asp Phe
        985                 990                 995

ggc ctt  tct cgg gga gag gag  gtt tat gtg aag aag  acg atg ggg      3075
Gly Leu  Ser Arg Gly Glu Glu  Val Tyr Val Lys Lys  Thr Met Gly
    1000                1005                1010

cgt ctc  cct gtg cgc tgg atg  gcc att gag tcc ctg  aac tac agt      3120
Arg Leu  Pro Val Arg Trp Met  Ala Ile Glu Ser Leu  Asn Tyr Ser
    1015                1020                1025

gtc tat  acc acc aag agt gat  gtc tgg tcc ttt gga  gtc ctt ctt      3165
Val Tyr  Thr Thr Lys Ser Asp  Val Trp Ser Phe Gly  Val Leu Leu
    1030                1035                1040

tgg gag  ata gtg agc ctt gga  ggt aca ccc tac tgt  ggc atg acc      3210
Trp Glu  Ile Val Ser Leu Gly  Gly Thr Pro Tyr Cys  Gly Met Thr
    1045                1050                1055

tgt gcc  gag ctc tat gaa aag  ctg ccc cag ggc tac  cgc atg gag      3255
Cys Ala  Glu Leu Tyr Glu Lys  Leu Pro Gln Gly Tyr  Arg Met Glu
    1060                1065                1070

cag cct  cga aac tgt gac gat  gaa gtg tac gag ctg  atg cgt cag      3300
Gln Pro  Arg Asn Cys Asp Asp  Glu Val Tyr Glu Leu  Met Arg Gln
    1075                1080                1085

tgc tgg  cgg gac cgt ccc tat  gag cga ccc ccc ttt  gcc cag att      3345
Cys Trp  Arg Asp Arg Pro Tyr  Glu Arg Pro Pro Phe  Ala Gln Ile
    1090                1095                1100

gcg cta  cag cta ggc cgc atg  ctg gaa gcc agg aag  gcc tat gtg      3390
Ala Leu  Gln Leu Gly Arg Met  Leu Glu Ala Arg Lys  Ala Tyr Val
    1105                1110                1115

aac atg  tcg ctg ttt gag aac  ttc act tac gcg ggc  att gat gcc      3435
```

```
Asn Met  Ser Leu Phe Glu Asn  Phe Thr Tyr Ala Gly  Ile Asp Ala
    1120                1125                1130

aca gct  gag gag gcc tga gctgccatcc agccagaacg tggctctgct          3483
Thr Ala  Glu Glu Ala
    1135

ggccggagca aactctgctg tctaacctgt gaccagtctg acccttacag cctctgactt  3543

aagctgcctc aaggaatttt tttaacttaa gggagaaaaa aagggatctg gggatggggt  3603

gggcttaggg gaactgggtt cccatgcttt gtaggtgtct catagctatc ctgggcatcc  3663

ttctttctag ttcagctgcc ccacaggtgt gtttcccatc ccactgctcc cccaacacaa  3723

acccccactc cagctccttc gcttaagcca gcactcacac cactaacatg ccctgttcag  3783

ctactcccac tcccggcctg tcattcagaa aaaaataaat gttctaataa gctccaaaaa  3843

aa                                                                 3845
```

<210> 2

<211> 1138

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Human Tie-1

<400> 2

```
Met Val Trp Arg Val Pro Pro Phe Leu Leu Pro Ile Leu Phe Leu Ala
1               5                  10                  15

Ser His Val Gly Ala Ala Val Asp Leu Thr Leu Leu Ala Asn Leu Arg
            20                  25                  30

Leu Thr Asp Pro Gln Arg Phe Phe Leu Thr Cys Val Ser Gly Glu Ala
        35                  40                  45

Gly Ala Gly Arg Gly Ser Asp Ala Trp Gly Pro Pro Leu Leu Leu Glu
    50                  55                  60

Lys Asp Asp Arg Ile Val Arg Thr Pro Pro Gly Pro Pro Leu Arg Leu
65                  70                  75                  80

Ala Arg Asn Gly Ser His Gln Val Thr Leu Arg Gly Phe Ser Lys Pro
                85                  90                  95

Ser Asp Leu Val Gly Val Phe Ser Cys Val Gly Gly Ala Gly Ala Arg
            100                 105                 110
```

```
Arg Thr Arg Val Ile Tyr Val His Asn Ser Pro Gly Ala His Leu Leu
        115                 120                 125

Pro Asp Lys Val Thr His Thr Val Asn Lys Gly Asp Thr Ala Val Leu
    130                 135                 140

Ser Ala Arg Val His Lys Glu Lys Gln Thr Asp Val Ile Trp Lys Ser
145                 150                 155                 160

Asn Gly Ser Tyr Phe Tyr Thr Leu Asp Trp His Glu Ala Gln Asp Gly
                165                 170                 175

Arg Phe Leu Leu Gln Leu Pro Asn Val Gln Pro Pro Ser Ser Gly Ile
            180                 185                 190

Tyr Ser Ala Thr Tyr Leu Glu Ala Ser Pro Leu Gly Ser Ala Phe Phe
        195                 200                 205

Arg Leu Ile Val Arg Gly Cys Gly Ala Gly Arg Trp Gly Pro Gly Cys
    210                 215                 220

Thr Lys Glu Cys Pro Gly Cys Leu His Gly Gly Val Cys His Asp His
225                 230                 235                 240

Asp Gly Glu Cys Val Cys Pro Pro Gly Phe Thr Gly Thr Arg Cys Glu
                245                 250                 255

Gln Ala Cys Arg Glu Gly Arg Phe Gly Gln Ser Cys Gln Glu Gln Cys
            260                 265                 270

Pro Gly Ile Ser Gly Cys Arg Gly Leu Thr Phe Cys Leu Pro Asp Pro
        275                 280                 285

Tyr Gly Cys Ser Cys Gly Ser Gly Trp Arg Gly Ser Gln Cys Gln Glu
    290                 295                 300

Ala Cys Ala Pro Gly His Phe Gly Ala Asp Cys Arg Leu Gln Cys Gln
305                 310                 315                 320

Cys Gln Asn Gly Gly Thr Cys Asp Arg Phe Ser Gly Cys Val Cys Pro
                325                 330                 335

Ser Gly Trp His Gly Val His Cys Glu Lys Ser Asp Arg Ile Pro Gln
            340                 345                 350

Ile Leu Asn Met Ala Ser Glu Leu Glu Phe Asn Leu Glu Thr Met Pro
        355                 360                 365

Arg Ile Asn Cys Ala Ala Ala Gly Asn Pro Phe Pro Val Arg Gly Ser
    370                 375                 380
```

```
Ile Glu Leu Arg Lys Pro Asp Gly Thr Val Leu Leu Ser Thr Lys Ala
385                 390                 395                 400

Ile Val Glu Pro Glu Lys Thr Thr Ala Glu Phe Glu Val Pro Arg Leu
                405                 410                 415

Val Leu Ala Asp Ser Gly Phe Trp Glu Cys Arg Val Ser Thr Ser Gly
            420                 425                 430
/

Gly Gln Asp Ser Arg Arg Phe Lys Val Asn Val Lys Val Pro Pro Val
        435                 440                 445

Pro Leu Ala Ala Pro Arg Leu Leu Thr Lys Gln Ser Arg Gln Leu Val
    450                 455                 460

Val Ser Pro Leu Val Ser Phe Ser Gly Asp Gly Pro Ile Ser Thr Val
465                 470                 475                 480

Arg Leu His Tyr Arg Pro Gln Asp Ser Thr Met Asp Trp Ser Thr Ile
                485                 490                 495

Val Val Asp Pro Ser Glu Asn Val Thr Leu Met Asn Leu Arg Pro Lys
            500                 505                 510

Thr Gly Tyr Ser Val Arg Val Gln Leu Ser Arg Pro Gly Glu Gly Gly
        515                 520                 525

Glu Gly Ala Trp Gly Pro Pro Thr Leu Met Thr Thr Asp Cys Pro Glu
    530                 535                 540

Pro Leu Leu Gln Pro Trp Leu Glu Gly Trp His Val Glu Gly Thr Asp
545                 550                 555                 560

Arg Leu Arg Val Ser Trp Ser Leu Pro Leu Val Pro Gly Pro Leu Val
                565                 570                 575

Gly Asp Gly Phe Leu Leu Arg Leu Trp Asp Gly Thr Arg Gly Gln Glu
            580                 585                 590

Arg Arg Glu Asn Val Ser Ser Pro Gln Ala Arg Thr Ala Leu Leu Thr
        595                 600                 605

Gly Leu Thr Pro Gly Thr His Tyr Gln Leu Asp Val Gln Leu Tyr His
    610                 615                 620

Cys Thr Leu Leu Gly Pro Ala Ser Pro Pro Ala His Val Leu Leu Pro
625                 630                 635                 640

Pro Ser Gly Pro Pro Ala Pro Arg His Leu His Ala Gln Ala Leu Ser
                645                 650                 655
```

```
Asp Ser Glu Ile Gln Leu Thr Trp Lys His Pro Glu Ala Leu Pro Gly
            660                 665                 670

Pro Ile Ser Lys Tyr Val Val Glu Val Gln Val Ala Gly Gly Ala Gly
        675                 680                 685

Asp Pro Leu Trp Ile Asp Val Asp Arg Pro Glu Glu Thr Ser Thr Ile
    690                 695                 700

Ile Arg Gly Leu Asn Ala Ser Thr Arg Tyr Leu Phe Arg Met Arg Ala
705                 710                 715                 720

Ser Ile Gln Gly Leu Gly Asp Trp Ser Asn Thr Val Glu Glu Ser Thr
                725                 730                 735

Leu Gly Asn Gly Leu Gln Ala Glu Gly Pro Val Gln Glu Ser Arg Ala
            740                 745                 750

Ala Glu Glu Gly Leu Asp Gln Gln Leu Ile Leu Ala Val Val Gly Ser
        755                 760                 765

Val Ser Ala Thr Cys Leu Thr Ile Leu Ala Ala Leu Leu Thr Leu Val
    770                 775                 780

Cys Ile Arg Arg Ser Cys Leu His Arg Arg Arg Thr Phe Thr Tyr Gln
785                 790                 795                 800

Ser Gly Ser Gly Glu Glu Thr Ile Leu Gln Phe Ser Ser Gly Thr Leu
                805                 810                 815

Thr Leu Thr Arg Arg Pro Lys Leu Gln Pro Glu Pro Leu Ser Tyr Pro
            820                 825                 830

Val Leu Glu Trp Glu Asp Ile Thr Phe Glu Asp Leu Ile Gly Glu Gly
        835                 840                 845

Asn Phe Gly Gln Val Ile Arg Ala Met Ile Lys Lys Asp Gly Leu Lys
    850                 855                 860

Met Asn Ala Ala Ile Lys Met Leu Lys Glu Tyr Ala Ser Glu Asn Asp
865                 870                 875                 880

His Arg Asp Phe Ala Gly Glu Leu Glu Val Leu Cys Lys Leu Gly His
                885                 890                 895

His Pro Asn Ile Ile Asn Leu Leu Gly Ala Cys Lys Asn Arg Gly Tyr
            900                 905                 910

Leu Tyr Ile Ala Ile Glu Tyr Ala Pro Tyr Gly Asn Leu Leu Asp Phe
        915                 920                 925
```

```
Leu Arg Lys Ser Arg Val Leu Glu Thr Asp Pro Ala Phe Ala Arg Glu
    930                 935                 940

His Gly Thr Ala Ser Thr Leu Ser Ser Arg Gln Leu Leu Arg Phe Ala
945                 950                 955                 960

Ser Asp Ala Ala Asn Gly Met Gln Tyr Leu Ser Glu Lys Gln Phe Ile
                965                 970                 975

His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Gly Glu Asn Leu Ala
            980                 985                 990

Ser Lys Ile Ala Asp Phe Gly Leu  Ser Arg Gly Glu Glu  Val Tyr Val
        995                 1000                1005

Lys Lys  Thr Met Gly Arg Leu  Pro Val Arg Trp Met  Ala Ile Glu
    1010                1015                1020

Ser Leu  Asn Tyr Ser Val Tyr  Thr Thr Lys Ser Asp  Val Trp Ser
    1025                1030                1035

Phe Gly  Val Leu Leu Trp Glu  Ile Val Ser Leu Gly  Gly Thr Pro
    1040                1045                1050

Tyr Cys  Gly Met Thr Cys Ala  Glu Leu Tyr Glu Lys  Leu Pro Gln
    1055                1060                1065

Gly Tyr  Arg Met Glu Gln Pro  Arg Asn Cys Asp Asp  Glu Val Tyr
    1070                1075                1080

Glu Leu  Met Arg Gln Cys Trp  Arg Asp Arg Pro Tyr  Glu Arg Pro
    1085                1090                1095

Pro Phe  Ala Gln Ile Ala Leu  Gln Leu Gly Arg Met  Leu Glu Ala
    1100                1105                1110

Arg Lys  Ala Tyr Val Asn Met  Ser Leu Phe Glu Asn  Phe Thr Tyr
    1115                1120                1125

Ala Gly  Ile Asp Ala Thr Ala  Glu Glu Ala
    1130                1135
```

<210> 3

<211> 4138

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (149)..(3523)

<220>

<221> misc_feature

<223> Human Tie-2

<400> 3

```
cttctgtgct gttccttctt gcctctaact tgtaaacaag acgtactagg acgatgctaa      60

tggaaagtca caaaccgctg ggtttttgaa aggatccttg ggacctcatg cacatttgtg     120

gaaactggat ggagagattt ggggaagc atg gac tct tta gcc agc tta gtt         172
                               Met Asp Ser Leu Ala Ser Leu Val
                               1               5

ctc tgt gga gtc agc ttg ctc ctt tct gga act gtg gaa ggt gcc atg       220
Leu Cys Gly Val Ser Leu Leu Leu Ser Gly Thr Val Glu Gly Ala Met
    10                  15                  20

gac ttg atc ttg atc aat tcc cta cct ctt gta tct gat gct gaa aca       268
Asp Leu Ile Leu Ile Asn Ser Leu Pro Leu Val Ser Asp Ala Glu Thr
25                  30                  35                  40

tct ctc acc tgc att gcc tct ggg tgg cgc ccc cat gag ccc atc acc       316
Ser Leu Thr Cys Ile Ala Ser Gly Trp Arg Pro His Glu Pro Ile Thr
                45                  50                  55

ata gga agg gac ttt gaa gcc tta atg aac cag cac cag gat ccg ctg       364
Ile Gly Arg Asp Phe Glu Ala Leu Met Asn Gln His Gln Asp Pro Leu
            60                  65                  70

gaa gtt act caa gat gtg acc aga gaa tgg gct aaa aaa gtt gtt tgg       412
Glu Val Thr Gln Asp Val Thr Arg Glu Trp Ala Lys Lys Val Val Trp
        75                  80                  85

aag aga gaa aag gct agt aag atc aat ggt gct tat ttc tgt gaa ggg       460
Lys Arg Glu Lys Ala Ser Lys Ile Asn Gly Ala Tyr Phe Cys Glu Gly
    90                  95                  100

cga gtt cga gga gag gca atc agg ata cga acc atg aag atg cgt caa       508
Arg Val Arg Gly Glu Ala Ile Arg Ile Arg Thr Met Lys Met Arg Gln
105                 110                 115                 120

caa gct tcc ttc cta cca gct act tta act atg act gtg gac aag gga       556
Gln Ala Ser Phe Leu Pro Ala Thr Leu Thr Met Thr Val Asp Lys Gly
                125                 130                 135

gat aac gtg aac ata tct ttc aaa aag gta ttg att aaa gaa gaa gat       604
Asp Asn Val Asn Ile Ser Phe Lys Lys Val Leu Ile Lys Glu Glu Asp
            140                 145                 150

gca gtg att tac aaa aat ggt tcc ttc atc cat tca gtg ccc cgg cat       652
Ala Val Ile Tyr Lys Asn Gly Ser Phe Ile His Ser Val Pro Arg His
        155                 160                 165

gaa gta cct gat att cta gaa gta cac ctg cct cat gct cag ccc cag       700
Glu Val Pro Asp Ile Leu Glu Val His Leu Pro His Ala Gln Pro Gln
    170                 175                 180

gat gct gga gtg tac tcg gcc agg tat ata gga gga aac ctc ttc acc       748
```

```
Asp Ala Gly Val Tyr Ser Ala Arg Tyr Ile Gly Gly Asn Leu Phe Thr
185                 190                 195                 200

tcg gcc ttc acc agg ctg ata gtc cgg aga tgt gaa gcc cag aag tgg      796
Ser Ala Phe Thr Arg Leu Ile Val Arg Arg Cys Glu Ala Gln Lys Trp
                205                 210                 215

gga cct gaa tgc aac cat ctc tgt act gct tgt atg aac aat ggt gtc      844
Gly Pro Glu Cys Asn His Leu Cys Thr Ala Cys Met Asn Asn Gly Val
            220                 225                 230

tgc cat gaa gat act gga gaa tgc att tgc cct cct ggg ttt atg gga      892
Cys His Glu Asp Thr Gly Glu Cys Ile Cys Pro Pro Gly Phe Met Gly
        235                 240                 245

agg acg tgt gag aag gct tgt gaa ctg cac acg ttt ggc aga act tgt      940
Arg Thr Cys Glu Lys Ala Cys Glu Leu His Thr Phe Gly Arg Thr Cys
    250                 255                 260

aaa gaa agg tgc agt gga caa gag gga tgc aag tct tat gtg ttc tgt      988
Lys Glu Arg Cys Ser Gly Gln Glu Gly Cys Lys Ser Tyr Val Phe Cys
265                 270                 275                 280

ctc cct gac ccc tat ggg tgt tcc tgt gcc aca ggc tgg aag ggt ctg     1036
Leu Pro Asp Pro Tyr Gly Cys Ser Cys Ala Thr Gly Trp Lys Gly Leu
                285                 290                 295

cag tgc aat gaa gca tgc cac cct ggt ttt tac ggg cca gat tgt aag     1084
Gln Cys Asn Glu Ala Cys His Pro Gly Phe Tyr Gly Pro Asp Cys Lys
            300                 305                 310

ctt agg tgc agc tgc aac aat ggg gag atg tgt gat cgc ttc caa gga     1132
Leu Arg Cys Ser Cys Asn Asn Gly Glu Met Cys Asp Arg Phe Gln Gly
        315                 320                 325

tgt ctc tgc tct cca gga tgg cag ggg ctc cag tgt gag aga gaa ggc     1180
Cys Leu Cys Ser Pro Gly Trp Gln Gly Leu Gln Cys Glu Arg Glu Gly
    330                 335                 340

ata ccg agg atg acc cca aag ata gtg gat ttg cca gat cat ata gaa     1228
Ile Pro Arg Met Thr Pro Lys Ile Val Asp Leu Pro Asp His Ile Glu
345                 350                 355                 360

gta aac agt ggt aaa ttt aat ccc att tgc aaa gct tct ggc tgg ccg     1276
Val Asn Ser Gly Lys Phe Asn Pro Ile Cys Lys Ala Ser Gly Trp Pro
                365                 370                 375

cta cct act aat gaa gaa atg acc ctg gtg aag ccg gat ggg aca gtg     1324
Leu Pro Thr Asn Glu Glu Met Thr Leu Val Lys Pro Asp Gly Thr Val
            380                 385                 390

ctc cat cca aaa gac ttt aac cat acg gat cat ttc tca gta gcc ata     1372
Leu His Pro Lys Asp Phe Asn His Thr Asp His Phe Ser Val Ala Ile
        395                 400                 405

ttc acc atc cac cgg atc ctc ccc cct gac tca gga gtt tgg gtc tgc     1420
Phe Thr Ile His Arg Ile Leu Pro Pro Asp Ser Gly Val Trp Val Cys
    410                 415                 420

agt gtg aac aca gtg gct ggg atg gtg gaa aag ccc ttc aac att tct     1468
Ser Val Asn Thr Val Ala Gly Met Val Glu Lys Pro Phe Asn Ile Ser
425                 430                 435                 440

gtt aaa gtt ctt cca aag ccc ctg aat gcc cca aac gtg att gac act     1516
Val Lys Val Leu Pro Lys Pro Leu Asn Ala Pro Asn Val Ile Asp Thr
                445                 450                 455

gga cat aac ttt gct gtc atc aac atc agc tct gag cct tac ttt ggg     1564
```

```
Gly His Asn Phe Ala Val Ile Asn Ile Ser Ser Glu Pro Tyr Phe Gly
            460                 465                 470

gat gga cca atc aaa tcc aag aag ctt cta tac aaa ccc gtt aat cac     1612
Asp Gly Pro Ile Lys Ser Lys Lys Leu Leu Tyr Lys Pro Val Asn His
        475                 480                 485

tat gag gct tgg caa cat att caa gtg aca aat gag att gtt aca ctc     1660
Tyr Glu Ala Trp Gln His Ile Gln Val Thr Asn Glu Ile Val Thr Leu
    490                 495                 500

aac tat ttg gaa cct cgg aca gaa tat gaa ctc tgt gtg caa ctg gtc     1708
Asn Tyr Leu Glu Pro Arg Thr Glu Tyr Glu Leu Cys Val Gln Leu Val
505                 510                 515                 520

cgt cgt gga gag ggt ggg gaa ggg cat cct gga cct gtg aga cgc ttc     1756
Arg Arg Gly Glu Gly Gly Glu Gly His Pro Gly Pro Val Arg Arg Phe
                525                 530                 535

aca aca gct tct atc gga ctc cct cct cca aga ggt cta aat ctc ctg     1804
Thr Thr Ala Ser Ile Gly Leu Pro Pro Pro Arg Gly Leu Asn Leu Leu
            540                 545                 550

cct aaa agt cag acc act cta aat ttg acc tgg caa cca ata ttt cca     1852
Pro Lys Ser Gln Thr Thr Leu Asn Leu Thr Trp Gln Pro Ile Phe Pro
        555                 560                 565

agc tcg gaa gat gac ttt tat gtt gaa gtg gag aga agg tct gtg caa     1900
Ser Ser Glu Asp Asp Phe Tyr Val Glu Val Glu Arg Arg Ser Val Gln
    570                 575                 580

aaa agt gat cag cag aat att aaa gtt cca ggc aac ttg act tcg gtg     1948
Lys Ser Asp Gln Gln Asn Ile Lys Val Pro Gly Asn Leu Thr Ser Val
585                 590                 595                 600

cta ctt aac aac tta cat ccc agg gag cag tac gtg gtc cga gct aga     1996
Leu Leu Asn Asn Leu His Pro Arg Glu Gln Tyr Val Val Arg Ala Arg
                605                 610                 615

gtc aac acc aag gcc cag ggg gaa tgg agt gaa gat ctc act gct tgg     2044
Val Asn Thr Lys Ala Gln Gly Glu Trp Ser Glu Asp Leu Thr Ala Trp
            620                 625                 630

acc ctt agt gac att ctt cct cct caa cca gaa aac atc aag att tcc     2092
Thr Leu Ser Asp Ile Leu Pro Pro Gln Pro Glu Asn Ile Lys Ile Ser
        635                 640                 645

aac att aca cac tcc tcg gct gtg att tct tgg aca ata ttg gat ggc     2140
Asn Ile Thr His Ser Ser Ala Val Ile Ser Trp Thr Ile Leu Asp Gly
    650                 655                 660

tat tct att tct tct att act atc cgt tac aag gtt caa ggc aag aat     2188
Tyr Ser Ile Ser Ser Ile Thr Ile Arg Tyr Lys Val Gln Gly Lys Asn
665                 670                 675                 680

gaa gac cag cac gtt gat gtg aag ata aag aat gcc acc atc att cag     2236
Glu Asp Gln His Val Asp Val Lys Ile Lys Asn Ala Thr Ile Ile Gln
                685                 690                 695

tat cag ctc aag ggc cta gag cct gaa aca gca tac cag gtg gac att     2284
Tyr Gln Leu Lys Gly Leu Glu Pro Glu Thr Ala Tyr Gln Val Asp Ile
            700                 705                 710

ttt gca gag aac aac ata ggg tca agc aac cca gcc ttt tct cat gaa     2332
Phe Ala Glu Asn Asn Ile Gly Ser Ser Asn Pro Ala Phe Ser His Glu
        715                 720                 725

ctg gtg acc ctc cca gaa tct caa gca cca gcg gac ctc gga ggg ggg     2380
```

```
Leu Val Thr Leu Pro Glu Ser Gln Ala Pro Ala Asp Leu Gly Gly Gly
    730                 735                 740

aag atg ctg ctt ata gcc atc ctt ggc tct gct gga atg acc tgc ctg      2428
Lys Met Leu Leu Ile Ala Ile Leu Gly Ser Ala Gly Met Thr Cys Leu
745                 750                 755                 760

act gtg ctg ttg gcc ttt ctg atc ata ttg caa ttg aag agg gca aat      2476
Thr Val Leu Leu Ala Phe Leu Ile Ile Leu Gln Leu Lys Arg Ala Asn
                765                 770                 775

gtg caa agg aga atg gcc caa gcc ttc caa aac gtg agg gaa gaa cca      2524
Val Gln Arg Arg Met Ala Gln Ala Phe Gln Asn Val Arg Glu Glu Pro
            780                 785                 790

gct gtg cag ttc aac tca ggg act ctg gcc cta aac agg aag gtc aaa      2572
Ala Val Gln Phe Asn Ser Gly Thr Leu Ala Leu Asn Arg Lys Val Lys
        795                 800                 805

aac aac cca gat cct aca att tat cca gtg ctt gac tgg aat gac atc      2620
Asn Asn Pro Asp Pro Thr Ile Tyr Pro Val Leu Asp Trp Asn Asp Ile
    810                 815                 820

aaa ttt caa gat gtg att ggg gag ggc aat ttt ggc caa gtt ctt aag      2668
Lys Phe Gln Asp Val Ile Gly Glu Gly Asn Phe Gly Gln Val Leu Lys
825                 830                 835                 840

gcg cgc atc aag aag gat ggg tta cgg atg gat gct gcc atc aaa aga      2716
Ala Arg Ile Lys Lys Asp Gly Leu Arg Met Asp Ala Ala Ile Lys Arg
                845                 850                 855

atg aaa gaa tat gcc tcc aaa gat gat cac agg gac ttt gca gga gaa      2764
Met Lys Glu Tyr Ala Ser Lys Asp Asp His Arg Asp Phe Ala Gly Glu
            860                 865                 870

ctg gaa gtt ctt tgt aaa ctt gga cac cat cca aac atc atc aat ctc      2812
Leu Glu Val Leu Cys Lys Leu Gly His His Pro Asn Ile Ile Asn Leu
        875                 880                 885

tta gga gca tgt gaa cat cga ggc tac ttg tac ctg gcc att gag tac      2860
Leu Gly Ala Cys Glu His Arg Gly Tyr Leu Tyr Leu Ala Ile Glu Tyr
    890                 895                 900

gcg ccc cat gga aac ctt ctg gac ttc ctt cgc aag agc cgt gtg ctg      2908
Ala Pro His Gly Asn Leu Leu Asp Phe Leu Arg Lys Ser Arg Val Leu
905                 910                 915                 920

gag acg gac cca gca ttt gcc att gcc aat agc acc gcg tcc aca ctg      2956
Glu Thr Asp Pro Ala Phe Ala Ile Ala Asn Ser Thr Ala Ser Thr Leu
                925                 930                 935

tcc tcc cag cag ctc ctt cac ttc gct gcc gac gtg gcc cgg ggc atg      3004
Ser Ser Gln Gln Leu Leu His Phe Ala Ala Asp Val Ala Arg Gly Met
            940                 945                 950

gac tac ttg agc caa aaa cag ttt atc cac agg gat ctg gct gcc aga      3052
Asp Tyr Leu Ser Gln Lys Gln Phe Ile His Arg Asp Leu Ala Ala Arg
        955                 960                 965

aac att tta gtt ggt gaa aac tat gtg gca aaa ata gca gat ttt gga      3100
Asn Ile Leu Val Gly Glu Asn Tyr Val Ala Lys Ile Ala Asp Phe Gly
    970                 975                 980

ttg tcc cga ggt caa gag gtg tac gtg aaa aag aca atg gga agg ctc      3148
Leu Ser Arg Gly Gln Glu Val Tyr Val Lys Lys Thr Met Gly Arg Leu
985                 990                 995                 1000

cca gtg cgc tgg atg  gcc atc gag tca ctg  aat tac agt gtg tac        3193
```

```
Pro Val Arg Trp Met  Ala Ile Glu Ser Leu  Asn Tyr Ser Val Tyr
                1005                1010                1015

aca acc aac agt gat  gta tgg tcc tat ggt  gtg tta cta tgg gag       3238
Thr Thr Asn Ser Asp  Val Trp Ser Tyr Gly  Val Leu Leu Trp Glu
                1020                1025                1030

att gtt agc tta gga  ggc aca ccc tac tgc  ggg atg act tgt gca       3283
Ile Val Ser Leu Gly  Gly Thr Pro Tyr Cys  Gly Met Thr Cys Ala
                1035                1040                1045

gaa ctc tac gag aag  ctg ccc cag ggc tac  aga ctg gag aag ccc       3328
Glu Leu Tyr Glu Lys  Leu Pro Gln Gly Tyr  Arg Leu Glu Lys Pro
                1050                1055                1060

ctg aac tgt gat gat  gag gtg tat gat cta  atg aga caa tgc tgg       3373
Leu Asn Cys Asp Asp  Glu Val Tyr Asp Leu  Met Arg Gln Cys Trp
                1065                1070                1075

cgg gag aag cct tat  gag agg cca tca ttt  gcc cag ata ttg gtg       3418
Arg Glu Lys Pro Tyr  Glu Arg Pro Ser Phe  Ala Gln Ile Leu Val
                1080                1085                1090

tcc tta aac aga atg  tta gag gag cga aag  acc tac gtg aat acc       3463
Ser Leu Asn Arg Met  Leu Glu Glu Arg Lys  Thr Tyr Val Asn Thr
                1095                1100                1105

acg ctt tat gag aag  ttt act tat gca gga  att gac tgt tct gct       3508
Thr Leu Tyr Glu Lys  Phe Thr Tyr Ala Gly  Ile Asp Cys Ser Ala
                1110                1115                1120

gaa gaa gcg gcc tag gacagaacat ctgtataccc tctgtttccc tttcactggc     3563
Glu Glu Ala Ala

atgggagacc cttgacaact gctgagaaaa catgcctctg ccaaaggatg tgatatataa   3623

gtgtacatat gtgctggaat tctaacaagt cataggttaa tatttaagac actgaaaaat   3683

ctaagtgata taaatcagat tcttctctct cattttatcc ctcacctgta gcatgccagt   3743

cccgtttcat ttagtcatgt gaccactctg tcttgtgttt ccacagcctg caagttcagt   3803

ccaggatgct aacatctaaa aatagactta aatctcattg cttacaagcc taagaatctt   3863

tagagaagta tacataagtt taggataaaa taatgggatt ttcttttctt ttctctggta   3923

atattgactt gtatatttta agaaataaca gaaagcctgg gtgacatttg ggagacatgt   3983

gacatttata tattgaatta atatccctac atgtattgca cattgtaaaa agttttagtt   4043

ttgatgagtt gtgagtttac cttgtatact gtaggcacac tttgcactga tatatcatga   4103

gtgaataaat gtcttgccta ctcaaaaaaa aaaaa                              4138
```

<210> 4

<211> 1124

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Human Tie-2

<400> 4

```
Met Asp Ser Leu Ala Ser Leu Val Leu Cys Gly Val Ser Leu Leu Leu
1               5                  10                  15

Ser Gly Thr Val Glu Gly Ala Met Asp Leu Ile Leu Ile Asn Ser Leu
            20                  25                  30

Pro Leu Val Ser Asp Ala Glu Thr Ser Leu Thr Cys Ile Ala Ser Gly
        35                  40                  45

Trp Arg Pro His Glu Pro Ile Thr Ile Gly Arg Asp Phe Glu Ala Leu
    50                  55                  60

Met Asn Gln His Gln Asp Pro Leu Glu Val Thr Gln Asp Val Thr Arg
65                  70                  75                  80

Glu Trp Ala Lys Lys Val Val Trp Lys Arg Glu Lys Ala Ser Lys Ile
                85                  90                  95

Asn Gly Ala Tyr Phe Cys Glu Gly Arg Val Arg Gly Glu Ala Ile Arg
            100                 105                 110

Ile Arg Thr Met Lys Met Arg Gln Gln Ala Ser Phe Leu Pro Ala Thr
        115                 120                 125

Leu Thr Met Thr Val Asp Lys Gly Asp Asn Val Asn Ile Ser Phe Lys
    130                 135                 140

Lys Val Leu Ile Lys Glu Glu Asp Ala Val Ile Tyr Lys Asn Gly Ser
145                 150                 155                 160

Phe Ile His Ser Val Pro Arg His Glu Val Pro Asp Ile Leu Glu Val
                165                 170                 175

His Leu Pro His Ala Gln Pro Gln Asp Ala Gly Val Tyr Ser Ala Arg
            180                 185                 190

Tyr Ile Gly Gly Asn Leu Phe Thr Ser Ala Phe Thr Arg Leu Ile Val
        195                 200                 205

Arg Arg Cys Glu Ala Gln Lys Trp Gly Pro Glu Cys Asn His Leu Cys
    210                 215                 220

Thr Ala Cys Met Asn Asn Gly Val Cys His Glu Asp Thr Gly Glu Cys
225                 230                 235                 240

Ile Cys Pro Pro Gly Phe Met Gly Arg Thr Cys Glu Lys Ala Cys Glu
                245                 250                 255
```

```
Leu His Thr Phe Gly Arg Thr Cys Lys Glu Arg Cys Ser Gly Gln Glu
            260                 265                 270

Gly Cys Lys Ser Tyr Val Phe Cys Leu Pro Asp Pro Tyr Gly Cys Ser
        275                 280                 285

Cys Ala Thr Gly Trp Lys Gly Leu Gln Cys Asn Glu Ala Cys His Pro
    290                 295                 300

Gly Phe Tyr Gly Pro Asp Cys Lys Leu Arg Cys Ser Cys Asn Asn Gly
305                 310                 315                 320

Glu Met Cys Asp Arg Phe Gln Gly Cys Leu Cys Ser Pro Gly Trp Gln
                325                 330                 335

Gly Leu Gln Cys Glu Arg Glu Gly Ile Pro Arg Met Thr Pro Lys Ile
            340                 345                 350

Val Asp Leu Pro Asp His Ile Glu Val Asn Ser Gly Lys Phe Asn Pro
        355                 360                 365

Ile Cys Lys Ala Ser Gly Trp Pro Leu Pro Thr Asn Glu Glu Met Thr
    370                 375                 380

Leu Val Lys Pro Asp Gly Thr Val Leu His Pro Lys Asp Phe Asn His
385                 390                 395                 400

Thr Asp His Phe Ser Val Ala Ile Phe Thr Ile His Arg Ile Leu Pro
                405                 410                 415

Pro Asp Ser Gly Val Trp Val Cys Ser Val Asn Thr Val Ala Gly Met
            420                 425                 430

Val Glu Lys Pro Phe Asn Ile Ser Val Lys Val Leu Pro Lys Pro Leu
        435                 440                 445

Asn Ala Pro Asn Val Ile Asp Thr Gly His Asn Phe Ala Val Ile Asn
    450                 455                 460

Ile Ser Ser Glu Pro Tyr Phe Gly Asp Gly Pro Ile Lys Ser Lys Lys
465                 470                 475                 480

Leu Leu Tyr Lys Pro Val Asn His Tyr Glu Ala Trp Gln His Ile Gln
                485                 490                 495

Val Thr Asn Glu Ile Val Thr Leu Asn Tyr Leu Glu Pro Arg Thr Glu
            500                 505                 510

Tyr Glu Leu Cys Val Gln Leu Val Arg Arg Gly Glu Gly Gly Glu Gly
        515                 520                 525
```

```
His Pro Gly Pro Val Arg Arg Phe Thr Thr Ala Ser Ile Gly Leu Pro
    530                 535                 540

Pro Pro Arg Gly Leu Asn Leu Leu Pro Lys Ser Gln Thr Thr Leu Asn
545                 550                 555                 560

Leu Thr Trp Gln Pro Ile Phe Pro Ser Ser Glu Asp Asp Phe Tyr Val
                565                 570                 575

Glu Val Glu Arg Arg Ser Val Gln Lys Ser Asp Gln Gln Asn Ile Lys
            580                 585                 590

Val Pro Gly Asn Leu Thr Ser Val Leu Leu Asn Asn Leu His Pro Arg
        595                 600                 605

Glu Gln Tyr Val Val Arg Ala Arg Val Asn Thr Lys Ala Gln Gly Glu
    610                 615                 620

Trp Ser Glu Asp Leu Thr Ala Trp Thr Leu Ser Asp Ile Leu Pro Pro
625                 630                 635                 640

Gln Pro Glu Asn Ile Lys Ile Ser Asn Ile Thr His Ser Ser Ala Val
                645                 650                 655

Ile Ser Trp Thr Ile Leu Asp Gly Tyr Ser Ile Ser Ser Ile Thr Ile
            660                 665                 670

Arg Tyr Lys Val Gln Gly Lys Asn Glu Asp Gln His Val Asp Val Lys
        675                 680                 685

Ile Lys Asn Ala Thr Ile Ile Gln Tyr Gln Leu Lys Gly Leu Glu Pro
    690                 695                 700

Glu Thr Ala Tyr Gln Val Asp Ile Phe Ala Glu Asn Asn Ile Gly Ser
705                 710                 715                 720

Ser Asn Pro Ala Phe Ser His Glu Leu Val Thr Leu Pro Glu Ser Gln
                725                 730                 735

Ala Pro Ala Asp Leu Gly Gly Gly Lys Met Leu Leu Ile Ala Ile Leu
            740                 745                 750

Gly Ser Ala Gly Met Thr Cys Leu Thr Val Leu Leu Ala Phe Leu Ile
        755                 760                 765

Ile Leu Gln Leu Lys Arg Ala Asn Val Gln Arg Arg Met Ala Gln Ala
    770                 775                 780

Phe Gln Asn Val Arg Glu Glu Pro Ala Val Gln Phe Asn Ser Gly Thr
785                 790                 795                 800
```

```
Leu Ala Leu Asn Arg Lys Val Lys Asn Asn Pro Asp Pro Thr Ile Tyr
                805                 810                 815

Pro Val Leu Asp Trp Asn Asp Ile Lys Phe Gln Asp Val Ile Gly Glu
            820                 825                 830

Gly Asn Phe Gly Gln Val Leu Lys Ala Arg Ile Lys Lys Asp Gly Leu
        835                 840                 845

Arg Met Asp Ala Ala Ile Lys Arg Met Lys Glu Tyr Ala Ser Lys Asp
    850                 855                 860

Asp His Arg Asp Phe Ala Gly Glu Leu Glu Val Leu Cys Lys Leu Gly
865                 870                 875                 880

His His Pro Asn Ile Ile Asn Leu Leu Gly Ala Cys Glu His Arg Gly
                885                 890                 895

Tyr Leu Tyr Leu Ala Ile Glu Tyr Ala Pro His Gly Asn Leu Leu Asp
            900                 905                 910

Phe Leu Arg Lys Ser Arg Val Leu Glu Thr Asp Pro Ala Phe Ala Ile
        915                 920                 925

Ala Asn Ser Thr Ala Ser Thr Leu Ser Ser Gln Gln Leu Leu His Phe
    930                 935                 940

Ala Ala Asp Val Ala Arg Gly Met Asp Tyr Leu Ser Gln Lys Gln Phe
945                 950                 955                 960

Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Val Gly Glu Asn Tyr
                965                 970                 975

Val Ala Lys Ile Ala Asp Phe Gly Leu Ser Arg Gly Gln Glu Val Tyr
            980                 985                 990

Val Lys Lys Thr Met Gly Arg Leu  Pro Val Arg Trp Met  Ala Ile Glu
        995                 1000                1005

Ser Leu  Asn Tyr Ser Val Tyr  Thr Thr Asn Ser Asp  Val Trp Ser
    1010                1015                1020

Tyr Gly  Val Leu Leu Trp Glu  Ile Val Ser Leu Gly  Gly Thr Pro
    1025                1030                1035

Tyr Cys  Gly Met Thr Cys Ala  Glu Leu Tyr Glu Lys  Leu Pro Gln
    1040                1045                1050

Gly Tyr  Arg Leu Glu Lys Pro  Leu Asn Cys Asp Asp  Glu Val Tyr
    1055                1060                1065
```

```
Asp Leu  Met Arg Gln Cys Trp  Arg Glu Lys Pro Tyr  Glu Arg Pro
    1070                 1075                 1080

Ser Phe  Ala Gln Ile Leu Val  Ser Leu Asn Arg Met  Leu Glu Glu
    1085                 1090                 1095

Arg Lys  Thr Tyr Val Asn Thr  Thr Leu Tyr Glu Lys  Phe Thr Tyr
    1100                 1105                 1110

Ala Gly  Ile Asp Cys Ser Ala  Glu Glu Ala Ala
    1115                 1120
```

<210> 5

<211> 3041

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Human angiopoietin 1 (ANG-1), mRNA

<220>

<221> misc_feature

<222> (96)..(665)

<223> FBG; Region: Fibrinogen-related domains (FReDs)

<220>

<221> CDS

<222> (96)..(674)

<400> 5

```
gaaaaagaga ggaagagaaa ccatttagag actgtgcaga tgtatatcaa gctggtttta     60

ataaaagtgg aatctacact atttatatta ataat atg cca gaa ccc aaa aag       113
                                        Met Pro Glu Pro Lys Lys
                                        1               5

gtg ttt tgc aat atg gat gtc aat ggg gga ggt tgg act gta ata caa      161
Val Phe Cys Asn Met Asp Val Asn Gly Gly Gly Trp Thr Val Ile Gln
            10                  15                  20

cat cgt gaa gat gga agt cta gat ttc caa aga ggc tgg aag gaa tat      209
His Arg Glu Asp Gly Ser Leu Asp Phe Gln Arg Gly Trp Lys Glu Tyr
```

```
        25                  30                  35

aaa atg ggt ttt gga aat ccc tcc ggt gaa tat tgg ctg ggg aat gag      257
Lys Met Gly Phe Gly Asn Pro Ser Gly Glu Tyr Trp Leu Gly Asn Glu
    40                  45                  50

ttt att ttt gcc att acc agt cag agg cag tac atg cta aga att gag      305
Phe Ile Phe Ala Ile Thr Ser Gln Arg Gln Tyr Met Leu Arg Ile Glu
55                  60                  65                  70

tta atg gac tgg gaa ggg aac cga gcc tat tca cag tat gac aga ttc      353
Leu Met Asp Trp Glu Gly Asn Arg Ala Tyr Ser Gln Tyr Asp Arg Phe
                75                  80                  85

cac ata gga aat gaa aag caa aac tat agg ttg tat tta aaa ggt cac      401
His Ile Gly Asn Glu Lys Gln Asn Tyr Arg Leu Tyr Leu Lys Gly His
            90                  95                  100

act ggg aca gca gga aaa cag agc agc ctg atc tta cac ggt gct gat      449
Thr Gly Thr Ala Gly Lys Gln Ser Ser Leu Ile Leu His Gly Ala Asp
        105                 110                 115

ttc agc act aaa gat gct gat aat gac aac tgt atg tgc aaa tgt gcc      497
Phe Ser Thr Lys Asp Ala Asp Asn Asp Asn Cys Met Cys Lys Cys Ala
    120                 125                 130

ctc atg tta aca gga gga tgg tgg ttt gat gct tgt ggc ccc tcc aat      545
Leu Met Leu Thr Gly Gly Trp Trp Phe Asp Ala Cys Gly Pro Ser Asn
135                 140                 145                 150

cta aat gga atg ttc tat act gcg gga caa aac cat gga aaa ctg aat      593
Leu Asn Gly Met Phe Tyr Thr Ala Gly Gln Asn His Gly Lys Leu Asn
                155                 160                 165

ggg ata aag tgg cac tac ttc aaa ggg ccc agt tac tcc tta cgt tcc      641
Gly Ile Lys Trp His Tyr Phe Lys Gly Pro Ser Tyr Ser Leu Arg Ser
            170                 175                 180

aca act atg atg att cga cct tta gat ttt tga aagcgcaatg tcagaagcga    694
Thr Thr Met Met Ile Arg Pro Leu Asp Phe
        185                 190

ttatgaaagc aacaaagaaa tccggagaag ctgccaggtg agaaactgtt tgaaaacttc    754

agaagcaaac aatattgtct cccttccagc aataagtggt agttatgtga agtcaccaag    814

gttcttgacc gtgaatctgg agccgtttga gttcacaaga gtctctactt ggggtgacag    874

tgctcacgtg gctcgactat agaaaactcc actgactgtc gggctttaaa aagggaagaa    934

actgctgagc ttgctgtgct tcaaactact actggacctt attttggaac tatggtagcc    994

agatgataaa tatggttaat ttcatgtaaa acagaaaaaa agagtgaaaa agagaatata   1054

catgaagaat agaaacaagc ctgccataat cctttggaaa agatgtatta taccagtgaa   1114

aaggcgttat atctatgcaa acctactaac aaattatact gttgcacaat tttgataaaa   1174

atttagaaca gcattgtcct ctgagttggt taaatgttaa tggatttcag aagcctaatt   1234

ccagtatcat acttactagt tgatttctgc ttacccatct tcaaatgaaa attccatttt   1294

tgtaagccat aatgaactgt agtacatgga caataagtgt gtggtagaaa caaactccat   1354

tactctgatt tttgatacag ttttcagaaa aagaaatgaa cataatcaag taaggatgta   1414

tgtggtgaaa acttaccacc cccatactat ggttttcatt tactctaaaa actgattgaa   1474
```

tgatatataa atatatttat agcctgagta aagttaaaag aatgtaaaat atatcatcaa 1534
gttcttaaaa taatatacat gcatttaata tttcctttga tattatacag gaaagcaata 1594
ttttggagta tgttaagttg aagtaaaacc aagtactctg gagcagttca ttttacagta 1654
tctacttgca tgtgtataca tacatgtaac ttcattattt taaaaatatt tttagaactc 1714
caatactcac cctgttatgt cttgctaatt taaattttgc taattaactg aaacatgctt 1774
accagattca cactgttcca gtgtctataa aagaaacact ttgaagtcta taaaaaataa 1834
aataattata aatatcattg tacatagcat gtttatatct gcaaaaaacc taatagctaa 1894
ttaatctgga atatgcaaca ttgtccttaa ttgatgcaaa taacacaaat gctcaaagaa 1954
atctactata tcccttaatg aaatacatca ttcttcatat atttctcctt cagtccattc 2014
ccttaggcaa tttttaattt ttaaaaatta ttatcagggg agaaaaattg gcaaaactat 2074
tatatgtaag ggatatatat atacaaaaag aaaattaatc atagtcacct gactaagaaa 2134
ttctgactgc tagttgccat aaataactca atggaaatat tcctatggga taatgtattt 2194
taagtgaatt tttggggtgc ttgaagttac tgcattattt tatcaagaag tcttctctgc 2254
ctgtaagtgt ccaaggttat gacagtaaac agtttttatt aaaacatgag tcactatggg 2314
atgagaaaat tgaaataaag ctactgggcc tcctctcata aaagagacag ttgttggcaa 2374
ggtagcaata ccagtttcaa acttggtgac ttgatccact atgccttaat ggtttcctcc 2434
atttgagaaa ataaagctat tcacattgtt aagaaaaata ctttttaaag tttaccatca 2494
agtctttttt atatttatgt gtctgtattc tacccctttt tgccttacaa gtgatatttg 2554
caggtattat accatttttc tattcttggt ggcttcttca tagcaggtaa gcctctcctt 2614
ctaaaaactt ctcaactgtt ttcatttaag ggaaagaaaa tgagtatttt gtccttttgt 2674
gttcctacag acactttctt aaaccagttt ttggataaag aatactattt ccaaactcat 2734
attacaaaaa caaaataaaa taataaaaaa agaaagcatg atatttactg ttttgttgtc 2794
tgggtttgag aaatgaaata ttgtttccaa ttatttataa taaatcagta taaaatgttt 2854
tatgattgtt atgtgtatta tgtaatacgt acatgtttat ggcaatttaa catgtgtatt 2914
cttttcattt aattgtttca gaataggata attaggtatt cgaattttgt ctttaaaatt 2974
catgtggttt ctatgcaaag ttcttcatat catcacaaca ttatttgatt taaataaaat 3034
tgaaagt 3041

<210> 6
<211> 192
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature

<223> Human angiopoietin 1 (ANG-1), mRNA

<220>

<221> misc_feature

<222> (96)..(665)

<223> FBG; Region: Fibrinogen-related domains (FReDs)

<400> 6

Met Pro Glu Pro Lys Lys Val Phe Cys Asn Met Asp Val Asn Gly Gly
1 5 10 15

Gly Trp Thr Val Ile Gln His Arg Glu Asp Gly Ser Leu Asp Phe Gln
20 25 30

Arg Gly Trp Lys Glu Tyr Lys Met Gly Phe Gly Asn Pro Ser Gly Glu
35 40 45

Tyr Trp Leu Gly Asn Glu Phe Ile Phe Ala Ile Thr Ser Gln Arg Gln
50 55 60

Tyr Met Leu Arg Ile Glu Leu Met Asp Trp Glu Gly Asn Arg Ala Tyr
65 70 75 80

Ser Gln Tyr Asp Arg Phe His Ile Gly Asn Glu Lys Gln Asn Tyr Arg
85 90 95

Leu Tyr Leu Lys Gly His Thr Gly Thr Ala Gly Lys Gln Ser Ser Leu
100 105 110

Ile Leu His Gly Ala Asp Phe Ser Thr Lys Asp Ala Asp Asn Asp Asn
115 120 125

Cys Met Cys Lys Cys Ala Leu Met Leu Thr Gly Gly Trp Trp Phe Asp
130 135 140

Ala Cys Gly Pro Ser Asn Leu Asn Gly Met Phe Tyr Thr Ala Gly Gln
145 150 155 160

Asn His Gly Lys Leu Asn Gly Ile Lys Trp His Tyr Phe Lys Gly Pro
165 170 175

Ser Tyr Ser Leu Arg Ser Thr Thr Met Met Ile Arg Pro Leu Asp Phe
180 185 190

<210> 7

<211> 2269

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Human angiopoietin 2 (ANG-2), mRNA

<220>

<221> CDS

<222> (350)..(1840)

<400> 7

```
tgggttggtg tttatctcct cccagccttg agggagggaa caacactgta ggatctgggg     60

agagaggaac aaaggaccgt gaaagctgct ctgtaaaagc tgacacagcc ctcccaagtg    120

agcaggactg ttcttcccac tgcaatctga cagtttactg catgcctgga gagaacacag    180

cagtaaaaac caggtttgct actggaaaaa gaggaaagag aagactttca ttgacggacc    240

cagccatggc agcgtagcag ccctgcgttt cagacggcag cagctcggga ctctggacgt    300

gtgtttgccc tcaagtttgc taagctgctg gtttattact gaagaaaga atg tgg cag    358
                                                    Met Trp Gln
                                                    1

att gtt ttc ttt act ctg agc tgt gat ctt gtc ttg gcc gca gcc tat      406
Ile Val Phe Phe Thr Leu Ser Cys Asp Leu Val Leu Ala Ala Ala Tyr
    5                   10                  15

aac aac ttt cgg aag agc atg gac agc ata gga aag aag caa tat cag      454
Asn Asn Phe Arg Lys Ser Met Asp Ser Ile Gly Lys Lys Gln Tyr Gln
20                  25                  30                  35

gtc cag cat ggg tcc tgc agc tac act ttc ctc ctg cca gag atg gac      502
Val Gln His Gly Ser Cys Ser Tyr Thr Phe Leu Leu Pro Glu Met Asp
                40                  45                  50

aac tgc cgc tct tcc tcc agc ccc tac gtg tcc aat gct gtg cag agg      550
Asn Cys Arg Ser Ser Ser Ser Pro Tyr Val Ser Asn Ala Val Gln Arg
            55                  60                  65

gac gcg ccg ctc gaa tac gat gac tcg gtg cag agg ctg caa gtg ctg      598
Asp Ala Pro Leu Glu Tyr Asp Asp Ser Val Gln Arg Leu Gln Val Leu
        70                  75                  80

gag aac atc atg gaa aac aac act cag tgg cta atg aag ctt gag aat      646
Glu Asn Ile Met Glu Asn Asn Thr Gln Trp Leu Met Lys Leu Glu Asn
    85                  90                  95

tat atc cag gac aac atg aag aaa gaa atg gta gag ata cag cag aat      694
Tyr Ile Gln Asp Asn Met Lys Lys Glu Met Val Glu Ile Gln Gln Asn
100                 105                 110                 115

gca gta cag aac cag acg gct gtg atg ata gaa ata ggg aca aac ctg      742
Ala Val Gln Asn Gln Thr Ala Val Met Ile Glu Ile Gly Thr Asn Leu
                120                 125                 130
```

```
ttg aac caa aca gct gag caa acg cgg aag tta act gat gtg gaa gcc      790
Leu Asn Gln Thr Ala Glu Gln Thr Arg Lys Leu Thr Asp Val Glu Ala
            135                 140                 145

caa gta tta aat cag acc acg aga ctt gaa ctt cag ctc ttg gaa cac      838
Gln Val Leu Asn Gln Thr Thr Arg Leu Glu Leu Gln Leu Leu Glu His
        150                 155                 160

tcc ctc tcg aca aac aaa ttg gaa aaa cag att ttg gac cag acc agt      886
Ser Leu Ser Thr Asn Lys Leu Glu Lys Gln Ile Leu Asp Gln Thr Ser
    165                 170                 175

gaa ata aac aaa ttg caa gat aag aac agt ttc cta gaa aag aag gtg      934
Glu Ile Asn Lys Leu Gln Asp Lys Asn Ser Phe Leu Glu Lys Lys Val
180                 185                 190                 195

cta gct atg gaa gac aag cac atc atc caa cta cag tca ata aaa gaa      982
Leu Ala Met Glu Asp Lys His Ile Ile Gln Leu Gln Ser Ile Lys Glu
                200                 205                 210

gag aaa gat cag cta cag gtg tta gta tcc aag caa aat tcc atc att     1030
Glu Lys Asp Gln Leu Gln Val Leu Val Ser Lys Gln Asn Ser Ile Ile
            215                 220                 225

gaa gaa cta gaa aaa aaa ata gtg act gcc acg gtg aat aat tca gtt     1078
Glu Glu Leu Glu Lys Lys Ile Val Thr Ala Thr Val Asn Asn Ser Val
        230                 235                 240

ctt caa aag cag caa cat gat ctc atg gag aca gtt aat aac tta ctg     1126
Leu Gln Lys Gln Gln His Asp Leu Met Glu Thr Val Asn Asn Leu Leu
    245                 250                 255

act atg atg tcc aca tca aac tca gct aag gac ccc act gtt gct aaa     1174
Thr Met Met Ser Thr Ser Asn Ser Ala Lys Asp Pro Thr Val Ala Lys
260                 265                 270                 275

gaa gaa caa atc agc ttc aga gac tgt gct gaa gta ttc aaa tca gga     1222
Glu Glu Gln Ile Ser Phe Arg Asp Cys Ala Glu Val Phe Lys Ser Gly
                280                 285                 290

cac acc aca aat ggc atc tac acg tta aca ttc cct aat tct aca gaa     1270
His Thr Thr Asn Gly Ile Tyr Thr Leu Thr Phe Pro Asn Ser Thr Glu
            295                 300                 305

gag atc aag gcc tac tgt gac atg gaa gct gga gga ggc ggg tgg aca     1318
Glu Ile Lys Ala Tyr Cys Asp Met Glu Ala Gly Gly Gly Gly Trp Thr
        310                 315                 320

att att cag cga cgt gag gat ggc agc gtt gat ttt cag agg act tgg     1366
Ile Ile Gln Arg Arg Glu Asp Gly Ser Val Asp Phe Gln Arg Thr Trp
    325                 330                 335

aaa gaa tat aaa gtg gga ttt ggt aac cct tca gga gaa tat tgg ctg     1414
Lys Glu Tyr Lys Val Gly Phe Gly Asn Pro Ser Gly Glu Tyr Trp Leu
340                 345                 350                 355

gga aat gag ttt gtt tcg caa ctg act aat cag caa cgc tat gtg ctt     1462
Gly Asn Glu Phe Val Ser Gln Leu Thr Asn Gln Gln Arg Tyr Val Leu
                360                 365                 370

aaa ata cac ctt aaa gac tgg gaa ggg aat gag gct tac tca ttg tat     1510
Lys Ile His Leu Lys Asp Trp Glu Gly Asn Glu Ala Tyr Ser Leu Tyr
            375                 380                 385

gaa cat ttc tat ctc tca agt gaa gaa ctc aat tat agg att cac ctt     1558
Glu His Phe Tyr Leu Ser Ser Glu Glu Leu Asn Tyr Arg Ile His Leu
        390                 395                 400
```

```
aaa gga ctt aca ggg aca gcc ggc aaa ata agc agc atc agc caa cca     1606
Lys Gly Leu Thr Gly Thr Ala Gly Lys Ile Ser Ser Ile Ser Gln Pro
    405                 410                 415

gga aat gat ttt agc aca aag gat gga gac aac gac aaa tgt att tgc     1654
Gly Asn Asp Phe Ser Thr Lys Asp Gly Asp Asn Asp Lys Cys Ile Cys
420                 425                 430                 435

aaa tgt tca caa atg cta aca gga ggc tgg tgg ttt gat gca tgt ggt     1702
Lys Cys Ser Gln Met Leu Thr Gly Gly Trp Trp Phe Asp Ala Cys Gly
                440                 445                 450

cct tcc aac ttg aac gga atg tac tat cca cag agg cag aac aca aat     1750
Pro Ser Asn Leu Asn Gly Met Tyr Tyr Pro Gln Arg Gln Asn Thr Asn
            455                 460                 465

aag ttc aac ggc att aaa tgg tac tac tgg aaa ggc tca ggc tat tcg     1798
Lys Phe Asn Gly Ile Lys Trp Tyr Tyr Trp Lys Gly Ser Gly Tyr Ser
        470                 475                 480

ctc aag gcc aca acc atg atg atc cga cca gca gat ttc taa             1840
Leu Lys Ala Thr Thr Met Met Ile Arg Pro Ala Asp Phe
    485                 490                 495

acatcccagt ccacctgagg aactgtctcg aactattttc aaagacttaa gcccagtgca   1900

ctgaaagtca cggctgcgca ctgtgtcctc ttccaccaca gagggcgtgt gctcggtgct   1960

gacgggaccc acatgctcca gattagagcc tgtaaacttt atcacttaaa cttgcatcac   2020

ttaacggacc aaagcaagac cctaaacatc cataattgtg attagacaga acacctatgc   2080

aaagatgaac ccgaggctga gaatcagact gacagtttac agacgctgct gtcacaacca   2140

agaatgttat gtgcaagttt atcagtaaat aactggaaaa cagaacactt atgttataca   2200

atacagatca tcttggaact gcattcttct gagcactgtt tatacactgt gtaaataccc   2260

atatgtcct                                                           2269
```

<210> 8

<211> 496

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Human angiopoietin 2 (ANG-2), mRNA

<400> 8

```
Met Trp Gln Ile Val Phe Phe Thr Leu Ser Cys Asp Leu Val Leu Ala
1               5                   10                  15

Ala Ala Tyr Asn Asn Phe Arg Lys Ser Met Asp Ser Ile Gly Lys Lys
            20                  25                  30

Gln Tyr Gln Val Gln His Gly Ser Cys Ser Tyr Thr Phe Leu Leu Pro
```

```
        35                  40                  45

Glu Met Asp Asn Cys Arg Ser Ser Ser Ser Pro Tyr Val Ser Asn Ala
    50                  55                  60

Val Gln Arg Asp Ala Pro Leu Glu Tyr Asp Asp Ser Val Gln Arg Leu
65                  70                  75                  80

Gln Val Leu Glu Asn Ile Met Glu Asn Asn Thr Gln Trp Leu Met Lys
                85                  90                  95

Leu Glu Asn Tyr Ile Gln Asp Asn Met Lys Lys Glu Met Val Glu Ile
            100                 105                 110

Gln Gln Asn Ala Val Gln Asn Gln Thr Ala Val Met Ile Glu Ile Gly
        115                 120                 125

Thr Asn Leu Leu Asn Gln Thr Ala Glu Gln Thr Arg Lys Leu Thr Asp
    130                 135                 140

Val Glu Ala Gln Val Leu Asn Gln Thr Thr Arg Leu Glu Leu Gln Leu
145                 150                 155                 160

Leu Glu His Ser Leu Ser Thr Asn Lys Leu Glu Lys Gln Ile Leu Asp
                165                 170                 175

Gln Thr Ser Glu Ile Asn Lys Leu Gln Asp Lys Asn Ser Phe Leu Glu
            180                 185                 190

Lys Lys Val Leu Ala Met Glu Asp Lys His Ile Ile Gln Leu Gln Ser
        195                 200                 205

Ile Lys Glu Glu Lys Asp Gln Leu Gln Val Leu Val Ser Lys Gln Asn
    210                 215                 220

Ser Ile Ile Glu Glu Leu Glu Lys Lys Ile Val Thr Ala Thr Val Asn
225                 230                 235                 240

Asn Ser Val Leu Gln Lys Gln Gln His Asp Leu Met Glu Thr Val Asn
                245                 250                 255

Asn Leu Leu Thr Met Met Ser Thr Ser Asn Ser Ala Lys Asp Pro Thr
            260                 265                 270

Val Ala Lys Glu Glu Gln Ile Ser Phe Arg Asp Cys Ala Glu Val Phe
        275                 280                 285

Lys Ser Gly His Thr Thr Asn Gly Ile Tyr Thr Leu Thr Phe Pro Asn
    290                 295                 300

Ser Thr Glu Glu Ile Lys Ala Tyr Cys Asp Met Glu Ala Gly Gly Gly
```

305 310 315 320

Gly Trp Thr Ile Ile Gln Arg Arg Glu Asp Gly Ser Val Asp Phe Gln
325 330 335

Arg Thr Trp Lys Glu Tyr Lys Val Gly Phe Gly Asn Pro Ser Gly Glu
340 345 350

Tyr Trp Leu Gly Asn Glu Phe Val Ser Gln Leu Thr Asn Gln Gln Arg
355 360 365

Tyr Val Leu Lys Ile His Leu Lys Asp Trp Glu Gly Asn Glu Ala Tyr
370 375 380

Ser Leu Tyr Glu His Phe Tyr Leu Ser Ser Glu Glu Leu Asn Tyr Arg
385 390 395 400

Ile His Leu Lys Gly Leu Thr Gly Thr Ala Gly Lys Ile Ser Ser Ile
405 410 415

Ser Gln Pro Gly Asn Asp Phe Ser Thr Lys Asp Gly Asp Asn Asp Lys
420 425 430

Cys Ile Cys Lys Cys Ser Gln Met Leu Thr Gly Gly Trp Trp Phe Asp
435 440 445

Ala Cys Gly Pro Ser Asn Leu Asn Gly Met Tyr Tyr Pro Gln Arg Gln
450 455 460

Asn Thr Asn Lys Phe Asn Gly Ile Lys Trp Tyr Tyr Trp Lys Gly Ser
465 470 475 480

Gly Tyr Ser Leu Lys Ala Thr Thr Met Met Ile Arg Pro Ala Asp Phe
485 490 495

<210> 9

<211> 1957

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Human angiopoietin-3 (ANG-3), mRNA

<220>

<221> misc_feature

<222> (1497)..(1497)

<223> n= a or g or t or c

<220>

<221> CDS

<222> (106)..(1617)

<400> 9

```
ggtgcagctg caggcaagcc tggccactgt tggctgcagc aggacatccc aggcacagcc      60

cctagggctc tgagcagaca tccctcgcca ttgacacatc ttcag atg ctc tcc caa     117
                                                    Met Leu Ser Gln
                                                    1

cta gcc atg ctg cag ggc agc ctc ctc ctt gtg gtt gcc acc atg tct       165
Leu Ala Met Leu Gln Gly Ser Leu Leu Leu Val Val Ala Thr Met Ser
5                   10                  15                  20

gtg gct caa cag aca agg cag gag gcg gat agg ggc tgc gag aca ctt       213
Val Ala Gln Gln Thr Arg Gln Glu Ala Asp Arg Gly Cys Glu Thr Leu
                25                  30                  35

gta gtc cag cac ggc cac tgt agc tac acc ttc ttg ctg ccc aag tct       261
Val Val Gln His Gly His Cys Ser Tyr Thr Phe Leu Leu Pro Lys Ser
            40                  45                  50

gag ccc tgc cct ccg ggg cct gag gtc tcc agg gac tcc aac acc ctc       309
Glu Pro Cys Pro Pro Gly Pro Glu Val Ser Arg Asp Ser Asn Thr Leu
        55                  60                  65

cag aga gaa tca ctg gcc aac cca ctg cac ctg ggg aag ttg ccc acc       357
Gln Arg Glu Ser Leu Ala Asn Pro Leu His Leu Gly Lys Leu Pro Thr
    70                  75                  80

cag cag gtg aaa cag ctg gag cag gca ctg cag aac aac acg cag tgg       405
Gln Gln Val Lys Gln Leu Glu Gln Ala Leu Gln Asn Asn Thr Gln Trp
85                  90                  95                  100

ctg aag aag cta gag agg gcc atc aag acg atc ttg agg tcg aag ctg       453
Leu Lys Lys Leu Glu Arg Ala Ile Lys Thr Ile Leu Arg Ser Lys Leu
                105                 110                 115

gag cag gtc cag cag caa atg gcc cag aat cag acg gcc ccc atg cta       501
Glu Gln Val Gln Gln Gln Met Ala Gln Asn Gln Thr Ala Pro Met Leu
            120                 125                 130

gag ctg ggc acc agc ctc ctg aac cag acc act gcc cag atc cgc aag       549
Glu Leu Gly Thr Ser Leu Leu Asn Gln Thr Thr Ala Gln Ile Arg Lys
        135                 140                 145

ctg acc gac atg gag gct cag ctc ctg aac cag aca tca aga atg gat       597
Leu Thr Asp Met Glu Ala Gln Leu Leu Asn Gln Thr Ser Arg Met Asp
    150                 155                 160

gcc cag atg cca gag acc ttt ctg tcc acc aac aag ctg gag aac cag       645
Ala Gln Met Pro Glu Thr Phe Leu Ser Thr Asn Lys Leu Glu Asn Gln
165                 170                 175                 180

ctg ctg cta cag agg cag aag ctc cag cag ctt cag ggc caa aac agc       693
Leu Leu Leu Gln Arg Gln Lys Leu Gln Gln Leu Gln Gly Gln Asn Ser
```

```
                185                 190                 195

gcg ctc gag aag cgg ttg cag gcc ctg gag acc aag cag cag gag gag      741
Ala Leu Glu Lys Arg Leu Gln Ala Leu Glu Thr Lys Gln Gln Glu Glu
            200                 205                 210

ctg gcc agc atc ctc agc aag aag gcg aag ctg ctg aac acg ctg agc      789
Leu Ala Ser Ile Leu Ser Lys Lys Ala Lys Leu Leu Asn Thr Leu Ser
        215                 220                 225

cgc cag agc gcc gcc ctc acc aac atc gag cgc ggc ctg cgc ggt gtc      837
Arg Gln Ser Ala Ala Leu Thr Asn Ile Glu Arg Gly Leu Arg Gly Val
    230                 235                 240

agg cac aac tcc agc ctc ctg cag gac cag cag cac agc ctg cgc cag      885
Arg His Asn Ser Ser Leu Leu Gln Asp Gln Gln His Ser Leu Arg Gln
245                 250                 255                 260

ctg ctg gtg ttg ttg cgg cac ctg gtg caa gaa agg gct aac gcc tcg      933
Leu Leu Val Leu Leu Arg His Leu Val Gln Glu Arg Ala Asn Ala Ser
                265                 270                 275

gcc ccg gcc ttc ata atg gca ggt gag cag gtg ttc cag gac tgt gca      981
Ala Pro Ala Phe Ile Met Ala Gly Glu Gln Val Phe Gln Asp Cys Ala
            280                 285                 290

gag atc cag cgc tct ggg gcc agt gcc agt ggt gtg tac acc atc cag     1029
Glu Ile Gln Arg Ser Gly Ala Ser Ala Ser Gly Val Tyr Thr Ile Gln
        295                 300                 305

gtg tcc aat gca acg aag ccc agg aag gtg ttc tgt gac ctg cag agc     1077
Val Ser Asn Ala Thr Lys Pro Arg Lys Val Phe Cys Asp Leu Gln Ser
    310                 315                 320

agt gga ggc agg tgg acc ctc atc cag cgc cgt gag aat ggc acc gtg     1125
Ser Gly Gly Arg Trp Thr Leu Ile Gln Arg Arg Glu Asn Gly Thr Val
325                 330                 335                 340

aat ttt cag cgg aac tgg aag gat tac aaa cag ggc ttc gga gac cca     1173
Asn Phe Gln Arg Asn Trp Lys Asp Tyr Lys Gln Gly Phe Gly Asp Pro
                345                 350                 355

gct ggg gag cac tgg ctg ggc aat gaa gtg gtg cac cag ctc acc aga     1221
Ala Gly Glu His Trp Leu Gly Asn Glu Val Val His Gln Leu Thr Arg
            360                 365                 370

agg gca gcc tac tct ctg cgt gtg gag ctg caa gac tgg gaa ggc cac     1269
Arg Ala Ala Tyr Ser Leu Arg Val Glu Leu Gln Asp Trp Glu Gly His
        375                 380                 385

gag gcc tat gcc cag tac gaa cat ttc cac ctg ggc agt gag aac cag     1317
Glu Ala Tyr Ala Gln Tyr Glu His Phe His Leu Gly Ser Glu Asn Gln
    390                 395                 400

cta tac agg ctt tct gtg gtc ggg tac agc ggc tca gca ggg cgc cag     1365
Leu Tyr Arg Leu Ser Val Val Gly Tyr Ser Gly Ser Ala Gly Arg Gln
405                 410                 415                 420

agc agc ctg gtc ctg cag aac acc agc ttt agc acc ctt gac tca gac     1413
Ser Ser Leu Val Leu Gln Asn Thr Ser Phe Ser Thr Leu Asp Ser Asp
                425                 430                 435

aac gac cac tgt ctc tgc aag tgt gcc caa gtg atg tct gga ggg tgg     1461
Asn Asp His Cys Leu Cys Lys Cys Ala Gln Val Met Ser Gly Gly Trp
            440                 445                 450

tgg ttt gac gcc tgt ggc ctg tca aac ctc aac ggn gtc tac tac cac     1509
Trp Phe Asp Ala Cys Gly Leu Ser Asn Leu Asn Gly Val Tyr Tyr His
```

```
        455                 460                 465

gct ccc gac aac aag tac aag atg gac ggc atc cgc tgg cac tac ttc     1557
Ala Pro Asp Asn Lys Tyr Lys Met Asp Gly Ile Arg Trp His Tyr Phe
    470                 475                 480

aag ggc ccc agc tac tca ctg cgt gcc tct cgc atg atg ata cgg cct     1605
Lys Gly Pro Ser Tyr Ser Leu Arg Ala Ser Arg Met Met Ile Arg Pro
485                 490                 495                 500

ttg gac atc taa cgagcagctg tgccagaggc tggaccacac aggagaagct         1657
Leu Asp Ile

cggacttggc actcctggac aacctggacc cagatgcaag acactgtgcc accgccttcc   1717

ctgacaccct gggcttcctg agccagccct ccttgaccca gaagtccaga agggtcatct   1777

gccccccccac tcccctccgt ctgtgacatg gagggtgttc ggggcccatc cctctgatgt   1837

agtcctcgcc cctcttctct ccctcccccc tcaggggctc cctgcctgag ggtcacagta   1897

ccttgaatgg gctgagaaca gaccaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa   1957
```

<210> 10

<211> 503

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Human angiopoietin-3 (ANG-3), mRNA

<220>

<221> misc_feature

<222> (1497)..(1497)

<223> n= a or g or t or c

<400> 10

```
Met Leu Ser Gln Leu Ala Met Leu Gln Gly Ser Leu Leu Leu Val Val
1               5                   10                  15

Ala Thr Met Ser Val Ala Gln Gln Thr Arg Gln Glu Ala Asp Arg Gly
            20                  25                  30

Cys Glu Thr Leu Val Val Gln His Gly His Cys Ser Tyr Thr Phe Leu
        35                  40                  45

Leu Pro Lys Ser Glu Pro Cys Pro Pro Gly Pro Glu Val Ser Arg Asp
    50                  55                  60

Ser Asn Thr Leu Gln Arg Glu Ser Leu Ala Asn Pro Leu His Leu Gly
```

65 70 75 80

Lys Leu Pro Thr Gln Gln Val Lys Gln Leu Glu Gln Ala Leu Gln Asn
85 90 95

Asn Thr Gln Trp Leu Lys Lys Leu Glu Arg Ala Ile Lys Thr Ile Leu
100 105 110

Arg Ser Lys Leu Glu Gln Val Gln Gln Gln Met Ala Gln Asn Gln Thr
115 120 125

Ala Pro Met Leu Glu Leu Gly Thr Ser Leu Leu Asn Gln Thr Thr Ala
130 135 140

Gln Ile Arg Lys Leu Thr Asp Met Glu Ala Gln Leu Leu Asn Gln Thr
145 150 155 160

Ser Arg Met Asp Ala Gln Met Pro Glu Thr Phe Leu Ser Thr Asn Lys
165 170 175

Leu Glu Asn Gln Leu Leu Leu Gln Arg Gln Lys Leu Gln Gln Leu Gln
180 185 190

Gly Gln Asn Ser Ala Leu Glu Lys Arg Leu Gln Ala Leu Glu Thr Lys
195 200 205

Gln Gln Glu Glu Leu Ala Ser Ile Leu Ser Lys Lys Ala Lys Leu Leu
210 215 220

Asn Thr Leu Ser Arg Gln Ser Ala Ala Leu Thr Asn Ile Glu Arg Gly
225 230 235 240

Leu Arg Gly Val Arg His Asn Ser Ser Leu Leu Gln Asp Gln Gln His
245 250 255

Ser Leu Arg Gln Leu Leu Val Leu Leu Arg His Leu Val Gln Glu Arg
260 265 270

Ala Asn Ala Ser Ala Pro Ala Phe Ile Met Ala Gly Glu Gln Val Phe
275 280 285

Gln Asp Cys Ala Glu Ile Gln Arg Ser Gly Ala Ser Ala Ser Gly Val
290 295 300

Tyr Thr Ile Gln Val Ser Asn Ala Thr Lys Pro Arg Lys Val Phe Cys
305 310 315 320

Asp Leu Gln Ser Ser Gly Gly Arg Trp Thr Leu Ile Gln Arg Arg Glu
325 330 335

Asn Gly Thr Val Asn Phe Gln Arg Asn Trp Lys Asp Tyr Lys Gln Gly

340 345 350

Phe Gly Asp Pro Ala Gly Glu His Trp Leu Gly Asn Glu Val Val His
355 360 365

Gln Leu Thr Arg Arg Ala Ala Tyr Ser Leu Arg Val Glu Leu Gln Asp
370 375 380

Trp Glu Gly His Glu Ala Tyr Ala Gln Tyr Glu His Phe His Leu Gly
385 390 395 400

Ser Glu Asn Gln Leu Tyr Arg Leu Ser Val Val Gly Tyr Ser Gly Ser
405 410 415

Ala Gly Arg Gln Ser Ser Leu Val Leu Gln Asn Thr Ser Phe Ser Thr
420 425 430

Leu Asp Ser Asp Asn Asp His Cys Leu Cys Lys Cys Ala Gln Val Met
435 440 445

Ser Gly Gly Trp Trp Phe Asp Ala Cys Gly Leu Ser Asn Leu Asn Gly
450 455 460

Val Tyr Tyr His Ala Pro Asp Asn Lys Tyr Lys Met Asp Gly Ile Arg
465 470 475 480

Trp His Tyr Phe Lys Gly Pro Ser Tyr Ser Leu Arg Ala Ser Arg Met
485 490 495

Met Ile Arg Pro Leu Asp Ile
500

<210> 11

<211> 1512

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Human angiopoietin 4 (ANG-4), mRNA

<220>

<221> CDS

<222> (2)..(1510)

<400> 11

```
c atg ctc tcc cag cta gcc atg ctg cag ggc agc ctc ctc ctt gtg gtt      49
  Met Leu Ser Gln Leu Ala Met Leu Gln Gly Ser Leu Leu Leu Val Val
  1               5                  10                  15

gcc acc atg tct gtg gct caa cag aca agg cag gag gcg gat agg ggc      97
Ala Thr Met Ser Val Ala Gln Gln Thr Arg Gln Glu Ala Asp Arg Gly
            20                  25                  30

tgc gag aca ctt gta gtc cag cac ggc cac tgt agc tac acc ttc ttg     145
Cys Glu Thr Leu Val Val Gln His Gly His Cys Ser Tyr Thr Phe Leu
        35                  40                  45

ctg ccc aag tct gag ccc tgc cct ccg ggg cct gag gtc tcc agg gac     193
Leu Pro Lys Ser Glu Pro Cys Pro Pro Gly Pro Glu Val Ser Arg Asp
    50                  55                  60

tcc aac acc ctc cag aga gaa tca ctg gcc aac cca ctg cac ctg ggg     241
Ser Asn Thr Leu Gln Arg Glu Ser Leu Ala Asn Pro Leu His Leu Gly
65                  70                  75                  80

aag ttg ccc acc cag cag gtg aaa cag ctg gag cag gca ctg cag aac     289
Lys Leu Pro Thr Gln Gln Val Lys Gln Leu Glu Gln Ala Leu Gln Asn
                85                  90                  95

aac acg cag tgg ctg aag aag cta gag agg gcc atc aag acg atc ttg     337
Asn Thr Gln Trp Leu Lys Lys Leu Glu Arg Ala Ile Lys Thr Ile Leu
            100                 105                 110

agg tcg aag ctg gag cag gtc cag cag caa atg gcc cag aat cag acg     385
Arg Ser Lys Leu Glu Gln Val Gln Gln Gln Met Ala Gln Asn Gln Thr
        115                 120                 125

gcc ccc atg cta gag ctg ggc acc agc ctc ctg aac cag acc act gcc     433
Ala Pro Met Leu Glu Leu Gly Thr Ser Leu Leu Asn Gln Thr Thr Ala
    130                 135                 140

cag atc cgc aag ctg acc gac atg gag gct cag ctc ctg aac cag aca     481
Gln Ile Arg Lys Leu Thr Asp Met Glu Ala Gln Leu Leu Asn Gln Thr
145                 150                 155                 160

tca aga atg gat gcc cag atg cca gag acc ttt ctg tcc acc aac aag     529
Ser Arg Met Asp Ala Gln Met Pro Glu Thr Phe Leu Ser Thr Asn Lys
                165                 170                 175


ctg gag aac cag ctg ctg cta cag agg cag aag ctc cag cag ctt cag     577
Leu Glu Asn Gln Leu Leu Leu Gln Arg Gln Lys Leu Gln Gln Leu Gln
            180                 185                 190

ggc caa aac agc gcg ctc gag aag cgg ttg cag gcc ctg gag acc aag     625
Gly Gln Asn Ser Ala Leu Glu Lys Arg Leu Gln Ala Leu Glu Thr Lys
        195                 200                 205

cag cag gag gag ctg gcc agc atc ctc agc aag aag gcg aag ctg ctg     673
Gln Gln Glu Glu Leu Ala Ser Ile Leu Ser Lys Lys Ala Lys Leu Leu
    210                 215                 220

aac acg ctg agc cgc cag agc gcc gcc ctc acc aac atc gag cgc ggc     721
Asn Thr Leu Ser Arg Gln Ser Ala Ala Leu Thr Asn Ile Glu Arg Gly
225                 230                 235                 240

ctg cgc ggt gtc agg cac aac tcc agc ctc ctg cag gac cag cag cac     769
Leu Arg Gly Val Arg His Asn Ser Ser Leu Leu Gln Asp Gln Gln His
                245                 250                 255
```

```
agc ctg cgc cag ctg ctg gtg ttg ttg cgg cac ctg gtg caa gaa agg      817
Ser Leu Arg Gln Leu Leu Val Leu Leu Arg His Leu Val Gln Glu Arg
            260                 265                 270

gct aac gcc tcg gcc ccg gcc ttc ata atg gca ggt gag cag gtg ttc      865
Ala Asn Ala Ser Ala Pro Ala Phe Ile Met Ala Gly Glu Gln Val Phe
        275                 280                 285

cag gac tgt gca gag atc cag cgc tct ggg gcc agt gcc agt ggt gtc      913
Gln Asp Cys Ala Glu Ile Gln Arg Ser Gly Ala Ser Ala Ser Gly Val
    290                 295                 300

tac acc atc cag gtg tcc aat gca acg aag ccc agg aag gtg ttc tgt      961
Tyr Thr Ile Gln Val Ser Asn Ala Thr Lys Pro Arg Lys Val Phe Cys
305                 310                 315                 320

gac ctg cag agc agt gga ggc agg tgg acc ctc atc cag cgc cgt gag     1009
Asp Leu Gln Ser Ser Gly Gly Arg Trp Thr Leu Ile Gln Arg Arg Glu
                325                 330                 335

aat ggc acc gtg aat ttt cag cgg aac tgg aag gat tac aaa cag ggc     1057
Asn Gly Thr Val Asn Phe Gln Arg Asn Trp Lys Asp Tyr Lys Gln Gly
            340                 345                 350

ttc gga gac cca gct ggg gag cac tgg ctg ggc aat gaa gtg gtg cac     1105
Phe Gly Asp Pro Ala Gly Glu His Trp Leu Gly Asn Glu Val Val His
        355                 360                 365

cag ctc acc aga agg gca gcc tac tct ctg cgt gtg gag ctg caa gac     1153
Gln Leu Thr Arg Arg Ala Ala Tyr Ser Leu Arg Val Glu Leu Gln Asp
    370                 375                 380

tgg gaa ggc cac gag gcc tat gcc cag tac gaa cat ttc cac ctg ggc     1201
Trp Glu Gly His Glu Ala Tyr Ala Gln Tyr Glu His Phe His Leu Gly
385                 390                 395                 400

agt gag aac cag cta tac agg ctt tct gtg gtc ggg tac agc ggc tca     1249
Ser Glu Asn Gln Leu Tyr Arg Leu Ser Val Val Gly Tyr Ser Gly Ser
                405                 410                 415

gca ggg cgc cag agc agc ctg gtc ctg cag aac acc agc ttt agc acc     1297
Ala Gly Arg Gln Ser Ser Leu Val Leu Gln Asn Thr Ser Phe Ser Thr
            420                 425                 430

ctt gac tca gac aac gac cac tgt ctc tgc aag tgt gcc cag gtg atg     1345
Leu Asp Ser Asp Asn Asp His Cys Leu Cys Lys Cys Ala Gln Val Met
        435                 440                 445

tct gga ggg tgg tgg ttt gac gcc tgt ggc ctg tca aac ctc aac ggc     1393
Ser Gly Gly Trp Trp Phe Asp Ala Cys Gly Leu Ser Asn Leu Asn Gly
    450                 455                 460

gtc tac tac cac gct ccc gac aac aag tac aag atg gac ggc atc cgc     1441
Val Tyr Tyr His Ala Pro Asp Asn Lys Tyr Lys Met Asp Gly Ile Arg
465                 470                 475                 480

tgg cac tac ttc aag ggc ccc agc tac tca ctg cgt gcc tct cgc atg     1489
Trp His Tyr Phe Lys Gly Pro Ser Tyr Ser Leu Arg Ala Ser Arg Met
                485                 490                 495

atg ata cgg cct ttg gac atc ta                                     1512
Met Ile Arg Pro Leu Asp Ile
            500
```

<210> 12

<211> 503

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Human angiopoietin 4 (ANG-4), mRNA

<400> 12

Met Leu Ser Gln Leu Ala Met Leu Gln Gly Ser Leu Leu Leu Val Val
1 5 10 15

Ala Thr Met Ser Val Ala Gln Gln Thr Arg Gln Glu Ala Asp Arg Gly
20 25 30

Cys Glu Thr Leu Val Val Gln His Gly His Cys Ser Tyr Thr Phe Leu
35 40 45

Leu Pro Lys Ser Glu Pro Cys Pro Pro Gly Pro Glu Val Ser Arg Asp
50 55 60

Ser Asn Thr Leu Gln Arg Glu Ser Leu Ala Asn Pro Leu His Leu Gly
65 70 75 80

Lys Leu Pro Thr Gln Gln Val Lys Gln Leu Glu Gln Ala Leu Gln Asn
85 90 95

Asn Thr Gln Trp Leu Lys Lys Leu Glu Arg Ala Ile Lys Thr Ile Leu
100 105 110

Arg Ser Lys Leu Glu Gln Val Gln Gln Gln Met Ala Gln Asn Gln Thr
115 120 125

Ala Pro Met Leu Glu Leu Gly Thr Ser Leu Leu Asn Gln Thr Thr Ala
130 135 140

Gln Ile Arg Lys Leu Thr Asp Met Glu Ala Gln Leu Leu Asn Gln Thr
145 150 155 160

Ser Arg Met Asp Ala Gln Met Pro Glu Thr Phe Leu Ser Thr Asn Lys
165 170 175

*

Leu Glu Asn Gln Leu Leu Leu Gln Arg Gln Lys Leu Gln Gln Leu Gln
180 185 190

Gly Gln Asn Ser Ala Leu Glu Lys Arg Leu Gln Ala Leu Glu Thr Lys
195 200 205

```
Gln Gln Glu Glu Leu Ala Ser Ile Leu Ser Lys Lys Ala Lys Leu Leu
    210                 215                 220

Asn Thr Leu Ser Arg Gln Ser Ala Ala Leu Thr Asn Ile Glu Arg Gly
225                 230                 235                 240

Leu Arg Gly Val Arg His Asn Ser Ser Leu Leu Gln Asp Gln Gln His
                245                 250                 255

Ser Leu Arg Gln Leu Leu Val Leu Leu Arg His Leu Val Gln Glu Arg
            260                 265                 270

Ala Asn Ala Ser Ala Pro Ala Phe Ile Met Ala Gly Glu Gln Val Phe
        275                 280                 285

Gln Asp Cys Ala Glu Ile Gln Arg Ser Gly Ala Ser Ala Ser Gly Val
    290                 295                 300

Tyr Thr Ile Gln Val Ser Asn Ala Thr Lys Pro Arg Lys Val Phe Cys
305                 310                 315                 320

Asp Leu Gln Ser Ser Gly Gly Arg Trp Thr Leu Ile Gln Arg Arg Glu
                325                 330                 335

Asn Gly Thr Val Asn Phe Gln Arg Asn Trp Lys Asp Tyr Lys Gln Gly
            340                 345                 350

Phe Gly Asp Pro Ala Gly Glu His Trp Leu Gly Asn Glu Val Val His
        355                 360                 365

Gln Leu Thr Arg Arg Ala Ala Tyr Ser Leu Arg Val Glu Leu Gln Asp
    370                 375                 380

Trp Glu Gly His Glu Ala Tyr Ala Gln Tyr Glu His Phe His Leu Gly
385                 390                 395                 400

Ser Glu Asn Gln Leu Tyr Arg Leu Ser Val Val Gly Tyr Ser Gly Ser
                405                 410                 415

Ala Gly Arg Gln Ser Ser Leu Val Leu Gln Asn Thr Ser Phe Ser Thr
            420                 425                 430

Leu Asp Ser Asp Asn Asp His Cys Leu Cys Lys Cys Ala Gln Val Met
        435                 440                 445

Ser Gly Gly Trp Trp Phe Asp Ala Cys Gly Leu Ser Asn Leu Asn Gly
    450                 455                 460

Val Tyr Tyr His Ala Pro Asp Asn Lys Tyr Lys Met Asp Gly Ile Arg
465                 470                 475                 480
```

```
Trp His Tyr Phe Lys Gly Pro Ser Tyr Ser Leu Arg Ala Ser Arg Met
                485                 490                 495

Met Ile Arg Pro Leu Asp Ile
            500
```